Document:

<PAGE>

         [*] CONFIDENTIAL TREATMENT REQUESTED. THE REDACTED MATERIAL
                 HAS BEEN FILED SEPARATELY WITH THE COMMISSION.

                                  EXHIBIT 10.7

                                LICENSE AGREEMENT

     This Agreement made effective as of August 7, 1998 by and between NEORX
CORPORATION, a Washington corporation, having a place of business at 410 West
Harrison Street, Seattle, WA 98119 ("NEORX"), and THESEUS, LTD., a Delaware
corporation, having a place of business at One Financial Center, Boston, MA
02111 ("THESEUS").

                                   WITNESSETH:

     WHEREAS, NEORX holds rights to certain technology in the field of
compostions of matter useful for the diagnosis of disease; and

     WHEREAS, THESEUS desires to obtain rights to use the technology for the
diagnosis of disease, and NEORX is willing to grant such rights to THESEUS, upon
the terms and conditions set forth herein;

     NOW, THEREFORE, the parties hereto agree as follows:

                                 I. DEFINITIONS

     1.01 "Affiliate" shall mean any corporation or other business entity
controlled by, controlling or under common control with such party. For purposes
of this definition, "control" shall mean the ownership, directly or indirectly,
of thirty-five percent (35%) or more (or, if less, the maximum permitted by
applicable law) of the voting stock, equity, income or analogous interest in a
corporation or other business entity.

     1.02 "Annexin Licensed Patents" shall mean the compositions and methods
described in the patents and patent applications set forth in Schedule B
attached hereto, including any reissue, division, continuation,
continuation-in-part (to the extent the claims of such continuation-in-part are
entitled to the filing date of, and cover or correspond to the Annexin-related
subject matter of, an application in Schedule B) or extension thereof and all
corresponding foreign patents and patent applications thereof, that NEORX
controls. Schedule B may be amended from time to time by mutual written
agreement of the parties in accordance with Section 8.04.

     1.03 "Annexin Licensed Product" shall mean any product covered by a claim
of a Annexin Licensed Patent.

     1.04 "Disease State" shall mean a recognized class of disease such as
cancer, arthritis, heart disease, etc.

     1.05 "Effective Date" shall mean the date set forth in the first line of
this Agreement.

     1.06 "Field" shall mean the in vivo diagnosis of human disease, but not
diagnosis related to or using tissue plasminogen activator or any modification
or derivative thereof.

     1.07 "Licensed Ligands" shall mean any ligand described by the claims of
any of the Linker Licensed Patents in Schedule A.

                                      -1-
<PAGE>

           [*] CONFIDENTIAL TREATMENT REQUESTED. THE REDACTED MATERIAL
                 HAS BEEN FILED SEPARATELY WITH THE COMMISSION.

     1.08 "Licensed Linkers" shall mean any linker described by the claims of
any of the Linker Licensed Patents in Schedule A.

     1.09 "Licensed Product" shall mean any Annexin Licensed Product or Linker
Licensed Product.

     1.10 "Licensed Product" shall mean the entire world.

     1.11 "Linker Licensed Patents" shall mean the family of patents and patent
applications set forth in Schedule A attached hereto, including any reissue,
division, continuation, continuation-in-part (to the extent the claims of such
continuation-in-part are entitled to the filing date of, and cover or correspond
to the Licensed Ligand or Licensed Linker subject matter of, an application in
Schedule A) or extension thereof and all corresponding foreign patents and
patent applications thereof. Schedule A may be amended from time to time by
mutual written agreement of the parties in accordance with Section 8.04.

     1.12 "Linker Licensed Product" shall mean (a) any product identified in
Schedule C attached hereto or (b) any product added as a "Linker Licensed
Product" pursuant to Section 2.02. It is understood and agreed that the products
identified in Schedule C or to be added pursuant to Section 2.02 (I) are for use
only in Field, (ii) utilize a Licensed Ligand or a Licensed Linker with a
THESEUS Vector and (iii) do not include any product acquired or licensed,
directly or indirectly, from Diatide, Inc. or its Related Parties or licensees
or any product incorporating or based on the technology of Diatide, Inc.

     1.13 "NEORX Annexin Technology" shall mean NEORX's rights in the Annexin
Licensed Patents and any know-how and information controlled by NEORX that is
unique to the manufacture or use of Annexin and the practice of Annexin Licensed
Patents and that is disclosed by NEORX during the Research Program.

     1.14 "NEORX Linker Technology" shall mean NEORX's rights in the Linker
Licensed Patents and any know-how and information controlled by NEORX that is
unique to the manufacture or use of the Licensed Ligands or Licensed Linkers and
the practice of the Linker Licensed Patents and that is disclosed by NEORX
during the Research Program.

     1.15 "Net Sales" shall mean, with respect to a Licensed Product, the gross
amount invoiced during the Royalty Term by THESEUS and its Affiliates and
Sublicensees for such Licensed Product (including all related components) or for
services rendered using such Licensed Product, less (a) excise or sale taxes,
duties and other taxes imposed on the invoiced sale (excluding income or other
taxes levied with respect to gross receipts) and separately stated on the
invoice and (b) insurance and transportation costs separately itemized on the
invoice for shipping the Licensed Product to the purchaser. Net Sales shall not
include any transfer between THESEUS and its Affiliates or Sublicensees for
resale, but shall include the resale from THESEUS or its Affiliates or
Sublicensees to third parties. Any Licensed Product (including its related
components) sold or otherwise disposed in other than arm's length transaction or
for other property (e.g., barter) shall be deemed invoiced at its fair market
value in the country of sale or dispossession.

     1.16 "Related Party" shall mean any corporation or other business entity
controlled by, controlling or under common control with Diatide, Inc. For
purposes of this definition, "control" shall mean the ownership, directly or
indirectly, of fifty percent (50%) or more (or, if less, the maximum permitted
by applicable law) of the voting stock, equity, income or analogous interest in
a corporation or other business entity.

     1.17 "Research Program" shall mean the program described in Article IV.

     1.18 "Royalty Term" shall mean for each Licensed Product, on a
country-by-country basis, the later of (a) the date of expiration of the last to
expire of any patents or patent applications included in the Linker Licensed
patents and Annexin Licensed Patents with Valid Claims covering the Licensed
Product in any country in which it is made, used or sold or (b) ten (10) years
after first commercial sale to a third party (not an Affiliated or Sublicensee)
of the Licensed Product in the country after, if required, all regulatory
approvals to a market are received.

                                      -2-
<PAGE>

           [*] CONFIDENTIAL TREATMENT REQUESTED. THE REDACTED MATERIAL
                 HAS BEEN FILED SEPARATELY WITH THE COMMISSION.

     1.19 "Sublicensee" shall mean any third party to which THESEUS sublicenses,
in accordance with this Agreement, the right to make, have made, use or sell
Licensed Products.

     1.20 "THESEUS Vector" shall mean any proprietary molecule that targets a
cell receptor or a Disease State that THESEUS (a) owns or has licensed from a
third party (other than Diatide, Inc. or its Related Parties or licensees) or
NEORX hereunder, i.e., Annexin, and (b) has developed.

     1.21 "Valid Claim" shall mean a claim of a pending patent application that
has not been abandoned or an issued, unexpired patent that has not been held
invalid or unenforceable by a final decision of a court or government agency of
competent jurisdiction, which decision is unappealable or was not appealed
within the time allowed therefor.

                                   II. LICENSE

     2.01 Subject to the terms of this Agreement, NEORX hereby grants THESEUS a
nonexclusive license to the NEORX Linder Technology to make, use and sell Linker
Licensed Products within the Field In the Licensed Territory. THESEUS shall not
use the NEORX Linker Technology for any other purpose. THESEUS shall not have
the right to sublicense its rights under this Section 2.01, except to a wholly
owned subsidiary so long as it remains a wholly owned subsidiary.

     2.02 THESEUS, upon thirty (30) days' prior written notice to NEORX with
supporting information, may elect to expand, on a product-by-product basis, the
license granted in Section 2.01 by adding a product to the definition of "Linker
Licensed Product" that (a) is under development at THESEUS or its Affiliates and
about to enter a pivotal clinical trial, (b) is for use only in the Field, (c)
utilizes a Licensed Ligand or a Licensed Linker with a THESEUS Vector, (d) does
not relate to or incorporate a tissue plasminogen activator or any modification
or derivative thereof and (e) is not a product acquired or licensed, directly or
indirectly, from Diatide, Inc. or its Related Parties or licensees or
incorporating or based on the technology of Diatide, Inc.

     2.03 Subject to the terms of this Agreement, NEORX hereby grants THESEUS an
exclusive license to the NEORX Annexin Technology to make, use and sell Annexin
Licensed Products within the Field in the Licensed Territory. THESEUS shall not
use the NEORX Annexin Technology for any other purpose. THESEUS shall have the
right to sublicense its rights under this Section 2.03 with the prior written
consent of NEORX, which consent shall not be unreasonably withheld. It is
recognized and agreed that a portion of the NEORX Annexin Technology may be
licensed from third-party institutions and that it is subject to, and THESEUS
shall comply and perform in accordance with, the terms of the third-party
license agreement.

     2.04 THESEUS shall provide NEORX with written notice of the name, address
and scope of rights of each Sublicensee to which it intends to grant a
sublicense in accordance with this Agreement and within ten (10) days after the
completion of the grant or any amendment to the scope of the Sublicensee's
rights.

     2.05 During the next twelve (12) months, NEORX shall provide reasonable
assistance to THESEUS, upon THESEUS' request and at THESEUS' expense, in seeking
to acquire other rights to technology owned or controlled by Boehringer
Ingelheim that may be useful in connection with Annexin Licensed Products.

     2.06 THESEUS shall use reasonable and diligent efforts to develop and
commercialize Annexin Licensed Products and Linker Licensed Products.

                                  III. PAYMENTS

     3.01 In consideration of the licenses granted to THESEUS in Article II,
THESEUS shall pay to NEORX [*] in accordance with the following schedule:

          (a)  [*] within ten (10) days after execution of this Agreement;

                                      -3-
<PAGE>

           [*] CONFIDENTIAL TREATMENT REQUESTED. THE REDACTED MATERIAL
                 HAS BEEN FILED SEPARATELY WITH THE COMMISSION.

          (b)  [*] three (3) months after the Effective Date;

          (c)  [*] five (5) months after the Effective Date;

          (d)  [*] three (3) years after the Effective Date; provided, however,
that NEORX may, at its sole discretion, elect to receive common stock of THESEUS
having a then fair market value of [*]; and

          (e)  Interest at the rate of ten percent (10%) on the unpaid balance
of such [*], with the accrued interest thereon being paid semiannually after the
Effective Date.

     3.02 In further consideration of the licenses granted to THESEUS in Article
II:

          (a)  THESEUS shall issue and deliver to NEORX within ten (10) days of
the Effective Date an amount of common stock of THESEUS that constitutes, after
issuance, [*] of the sum of (i) the outstanding common stock of THESEUS and (ii)
the number of shares of common stock of THESEUS that would be issued upon
exercise of any outstanding options, warrants or other rights to purchase.
THESEUS represents and warrants that, until after issuance and delivery of such
common stock to NEORX, THESEUS has no issued, and has not granted any options,
warrants or other rights to purchase, any preferred stock of THESEUS.

          (b)  In the event THESEUS issues any common stock or preferred stock
or grants rights, options or warrants to purchase common stock or preferred
stock of THESEUS, THESEUS shall issue and deliver to NEORX an amount of such
common stock or preferred stock, as the case may be, that is, after issuance,
[*] of the common stock or preferred stock (i) issued by THESEUS and (ii)
issuable under such rights, options or warrants; provided, however, that such
obligation to issue stock to NEORX shall not apply to issuances or grants by
THESEUS occurring after THESEUS has issued its common stock or preferred stock
in an offering for which it receives in excess of [*] and the fair market value
paid for such stock (i.e., not including any premium attributable to license or
other rights, etc.) would establish a fair market value for all then outstanding
stock of THESEUS in excess of [*].

          (c)  With respect to any offering by THESEUS as to which NEORX is not
entitled to receive [*] thereof pursuant to Section 3.02(b) and until (but not
including) the time that THESEUS sells its common stock in a public offering for
an aggregate amount in excess of [*], NEORX shall have the right to purchase at
any offering an amount of shares up to its percentage interest in the then
outstanding shares of THESEUS, upon the same terms and conditions as the
offering.

          (d)  In the event THESEUS offers, prior to a public offering of stock
described in Section 3.02(c), registration rights to any purchaser of securities
of THESEUS, THESEUS shall offer NEORX the same registration rights for the stock
it holds.

          (e)  In the event, prior to a public offering of stock described in
Section 3.02(c), THESEUS is acquired (whether by merger, acquisition of its
stock, acquisition of substantially all of its assets or other form or
reorganization), NEORX may elect to receive for its common stock of THESEUS, in
place of what it would otherwise be entitled to receive pursuant to the
acquisition, an immediate cash payment of [*], which THESEUS shall promptly pay
or cause the acquirer to promptly pay to NEORX.

          (f)  All stock issued by THESEUS to NEORX pursuant to Section 3.02(a)
or (b) shall be fully paid-up and nonassessable when issued.

     3.03 In further consideration of the licenses granted to THESEUS in Article
II, THESEUS shall make the following milestone payments to NEORX:

          (a)  [*] upon submission of the first New Drug Application or Product
License Application in the United States of America for a Licensed Product.

                                      -4-
<PAGE>

           [*] CONFIDENTIAL TREATMENT REQUESTED. THE REDACTED MATERIAL
                 HAS BEEN FILED SEPARATELY WITH THE COMMISSION.

          (b)  [*] upon the first approval of a New Drug Application or Product
License Application in the United States of America;

          (c)  [*] upon submission of the first application for marketing
approval in a European country or Japan for a Licensed Product or, if in any
country where no approval is required, upon the first commercial sale of a
Licensed Product in the country; and

          (d)  [*] upon the first marketing approval in a European country or
Japan for a Licensed Product or, if in any country where no approval is
required, upon the first commercial sale of a Licensed Product in the country.

     Notwithstanding (c) and (d) of this Section 3.03, in no event shall such
milestones (c) and (d) be due later than the first commercial sale of a Licensed
Product outside of the United States of America.

     3.04 In further consideration of the licenses granted to THESEUS in Article
II, THESEUS shall pay NEORX on each anniversary of the Effective Date[*].

     3.05 In further consideration of the licenses granted to THESEUS in Article
II, THESEUS shall make the following royalty payments to NEORX on the Net Sales
of THESEUS, its Affiliates and its Sublicensees;

          (a)  With respect to all Annexin Licensed Products (including products
that are both Annexin Licensed Products and Linker Licensed Products):

               (i)  [*] of aggregate annual Net Sales of all such Annexin
Licensed Products up to and including [*] and

               (ii) [*] of aggregate annual Net Sales of all such Annexin
Licensed Products over [*]; provided, however, that THESEUS may elect to reduce
such [*] royalty rate to [*] as to all such Annexin Licensed Products by paying
NEORX [*] in addition to all other amounts due under this Agreement) no later
than one (1) year after the first approval of a New Drug Application or Product
License Application in the United States of America for such an Annexin Licensed
Product, if THESEUS is not then in breach of any other provision of this
Agreement; and

provided, however, that the royalty rates provided in (i) and (ii) of this
Section 3.05(a) shall be reduced by [*] for the Net Sales of an Annexin Licensed
Product in a country (but not to an amount less than [*] of the amount that
NEORX would owe any third party with respect to the Net Sales in the country) if
(A) the Royalty Term described in Section 1.18(a) for the Annexin Licensed
Product has expired (but the Royalty Term described in Section 1.18(b) has not)
and (B) the Annexin Licensed Product is experiencing material competition from
another product containing Annexin that was not manufactured or sold by THESEUS
and its Affiliates and Sublicensees, such material competition being deemed to
exist only if the gross sales of such competing product constitutes [*] of the
gross sales occurring in the country of the Annexin Licensed Product and other
Annexin products that are competitive (as reported by International Marketing
Statistics or, if not available, a comparable source); and provided further,
that in the vent the aggregate annual Net Sales of all such Annexin Licensed
Products exceed [*] (the "Break Point") and its is necessary to treat Net Sales
for certain Annexin Licensed Products and/or countries differently (i.e., the
foregoing [*] royalty reduction), then the amount of such Net Sales that are
deemed to be above the Break Point (i.e., to which a higher royalty rate is
applied under this Agreement) shall be equal to the worldwide aggregate annual
Net Sales in excess of the Break Point multiplied by the ratio of the Net Sales
for such Annexin Licensed Product and/or country to the worldwide aggregate
annual net Sales for all Annexin Licensed Products; the balance of such Net
Sales being deemed to be below the Break Point (i.e., to which a lower royalty
rate is applied); and

                                      -5-
<PAGE>

           [*] CONFIDENTIAL TREATMENT REQUESTED. THE REDACTED MATERIAL
                 HAS BEEN FILED SEPARATELY WITH THE COMMISSION.

          (b)  With respect to all Linker Licensed Products that are not also
Annexin Licensed Products:

               (i)  [*] of aggregate annual Net Sales of all such Linker
Licensed Products up to an including [*] and

               (ii) [*] of aggregate annual Net Sales of all such Linker
Licensed Products over[*].

     3.06 In further consideration of the licenses granted to THESEUS in Article
II, THESEUS shall pay NEORX (a) minimum annual royalties of [*] within thirty
(30) days after each anniversary of the first sale of an Annexin Licensed
product and after each anniversary of the first sale of a Linker Licensed
Product, which minimum annual royalties shall be reduced by, and have credited
against them, the royalties paid to NEORX by THESEUS with respect to all Annexin
Licensed Products or all Linker Licensed Products pursuant to Section 3.05(a) or
3.05(b), as the case may be, for the four (4) calendar quarter immediately
preceding the anniversary to which the minimum annual royalty payment applies
(e.g., royalties paid on all Annexin Licensed Products for such four (4)
quarters are creditable against the [*] annual minimum royalty payment due on
the anniversary of the first sale of an Annexin Licensed Product), and (b) [*]
of the consideration received by THESEUS from sublicensing any portion of the
NEORX Annexin Technology other than royalties (e.g., up-front and milestone
payments), such [*] to be paid within twenty (20) days after receipt of the
consideration and, in the event the consideration is other than cash, to be paid
in cash based on the fair market value of the consideration.

     3.07 THESEUS shall be responsible to NEORX for the accounting and
payment of all royalties, milestones and minimums as a result of milestones
or Net Sales by Affiliates and Sublicensees, THESEUS shall make royalty
payments due under Section 3.05) with respect to Net Sales in each calendar
quarter within thirty (30) days after the close of business for each calendar
quarter. At the time each royalty payment is due, THESEUS shall provide to
NEORX a written report setting forth for the calendar quarter the Net Sales
(in local currency and U.S. dollars, with applicable exchange rates pursuant
to Section 3.08 noted), the quantity of Licensed Product sold and the royalty
due and payable thereon, on a product-byproduct and country-by country basis
(including all deductions taken from the gross invoiced amount in determining
Net Sales).

     3.08 All Net Sales and royalties to NEORX under Section 3.05 shall be
calculated and paid in U.S. dollars at the rate of exchange set forth in THE
WALL STREET JOURNAL (WESTERN EDITION) for the last business day of the quarterly
period in which the Net Sales occurred.

     3.09 THESEUS shall keep, and shall cause its Affiliates and Sublicensees to
keep, complete and accurate records and books of account containing all
information required for the computation and verification of amounts to be paid
under this Agreement. At the request of NEORX not more frequently than once per
calendar year, such records and books of account may be inspected during
business hours by a certified public accountant appointed by NEORX and to whom
THESEUS has no reasonable objection to the extent necessary to verify the
accuracy of statements and shall be preserved for at least five (5) years from
the date of the statement to which they pertain. If, as a result of such
inspection, it is determined that royalties have been underpaid by more than [*]
for the period under inspection, THESEUS shall promptly reimburse NEORX for the
cost of such inspection.

     3.10 THESEUS acknowledges that NEORX's know-how, information and
consulting/research that it may receive pursuant to Article IV may be of
substantial value and may constitute valuable and substantial trade secrets of
NEORX. The parties acknowledge and agree that, for their mutual convenience and
after considering other alternatives, including larger or other forms of
payments, the payments to NEORX set forth in this Agreement, including the
structure and term of royalty payments, are an appropriate and mutually
convenient way of compensating NEORX.

                                      -6-
<PAGE>

           [*] CONFIDENTIAL TREATMENT REQUESTED. THE REDACTED MATERIAL
                 HAS BEEN FILED SEPARATELY WITH THE COMMISSION.

                              IV. RESEARCH SUPPORT

     4.01 Dr. Alan Fritzberg and Dr. Allan Green shall promptly define a two (2)
year Research program under which NEORX will assist THESEUS in labeling THESEUS
Vectors with Licensed Ligands or Licensed Linkers, such assistance not to
require more than one-half of full-time equivalent (FTE) from NEORX personnel.
NEORX may terminate the Research Program in the vent Dr. Alan Fritzberg or Dr.
Sudhakar Kasina are no longer employed by NEORX.

     4.02 Within ten (10) days after execution of this Agreement, THESEUS shall
pay [*], and thereafter on or before the first day of each succeeding calendar
quarter [*] until an aggregate [*] has been paid to NEORX under this Section
4.02, to support NEORX's efforts under the Research Program. Such payments of
[*] per quarter cannot be reduced or terminated early by THESEUS, regardless of
whether THESEUS seeks or requests NEORX's assistance, unless the Research
Program is terminated by NEORX. In addition, THESEUS shall pay for any travel
expenses or other extraordinary costs or expenses associated with the Research
Program that are beyond normal laboratory supplies (e.g. capital equipment). All
travel by NEORX personnel shall be mutually agreed upon in advance.

     4.03 With respect to any patentable inventions (sole or joint) occurring in
the course of the Research Program being performed by THESEUS and NEORX:

          (a)  THESEUS shall have the nonexclusive right to use any inventions
in the Field with Linker Licensed Products and the exclusive right to use any
inventions in the Field with Annexin Licensed Products, and

          (b)  NEORX shall have the exclusive right to use any inventions
outside the Field and the nonexclusive right (with right to sublicense) to use
any inventions inside the Field with Linker Licensed Products.

     4.04 NEORX and THESEUS shall have the right to publish or present
information related to the results of the Research Program; provided, however,
that the proposed publication or presentation is disclosed to the other party at
least one (1) month prior to submission, but not less than two (2) months prior
to, the proposed publication or presentation, the parties give due consideration
to filing any desired patent applications and consideration is given to the
authorship of the publications including representatives from both parties, if
appropriate.

                             V. TERM AND TERMINATION

     5.01 The term of this Agreement shall commence on the Effective Date and
continue, unless terminated earlier, until the last to expire of any Royalty
Term. Upon expiration of the Royalty Term as to any Licensed Product, the
license for such Licensed Product shall become fully paid-up and nonexclusive.

     5.02 Each party shall have the right to terminate this Agreement in case of
default by the other party with respect to any payment obligation or material
obligation hereunder and which default continues for fifteen (15) days, in the
case of a default in payment, or ninety (90) days, in the case of any other
default, after receipt of written notice of such default. Termination of this
Agreement shall be in addition to any other remedies available for default under
this Agreement, which remedies shall survive termination of this Agreement.

     5.03 NEORX may terminate this Agreement upon thirty (30) days' notice in
the event THESEUS, within twelve (12) months after the Effective Date (a) does
not have at least three senior level employees actively working on product
development, research and development, or clinical trials on a full-time basis
for an Annexin Licensed Product and a Linker Licensed Product or (b) has not
initiated a phase II clinical trial for an Annexin Licensed Product.

                                      -7-
<PAGE>

           [*] CONFIDENTIAL TREATMENT REQUESTED. THE REDACTED MATERIAL
                 HAS BEEN FILED SEPARATELY WITH THE COMMISSION.

     5.04 Termination or expiration of this Agreement shall not terminate any
accrued obligations, including THESEUS' obligation to pay in full the amount due
under Section 3.01, and the rights and obligations under Sections 3.02, 3.09,
8.02, 8.05, 8.06, 8.07 and 8.09, all of which shall survive termination or
expiration of this Agreement. Section 4.03 shall survive expiration (but not
termination) of this Agreement.

                                  VI. WARRANTY

     6.01 Each party represents to the other party that is has the authority to
enter into this Agreement.

     6.02 NEORX MAKES NO REPRESENTATION OR WARRANTY WITH RESPECT TO THE LINKER
LICENSED PATENTS, ANNEXIN LICENSED PATENTS, OTHER NEORX LINKER TECHNOLOGY AND
NEORX ANNEXIN TECHNOLOGY, LINKER LICENSED PRODUCTS AND ANNEXIN LICENSED
PRODUCTS, EXPRESS OR IMPLIED, INCLUDING WARRANTIES OF MERCHANTABILITY, FITNESS
FOR A PARTICULAR PURPOSE, PATENT ABILITY, ENFORCEABILITY, NONINFRINGEMENT OR THE
RIGHTS OF OTHERS, OR THE EXCLUSIVITY OF NEORX'S RIGHTS. IT IS RECOGNIZED AND
AGREED BY THESEUS THAT CERTAIN PATENTS ARE OWNED BY STANFORD UNIVERSITY, WHICH
WILL BE ACQUIRED DIRECTLY BY THESEUS, AND NOT THROUGH ANY RIGHTS HEREUNDER, THAT
NEORX'S INTEREST IN THE ANNEXIN LICENSED PATENTS MAY BE JOINTLY HELD WITH, OR
SUBJECT TO THE RIGHTS OF, OTHER PARTIES, INCLUDING THE UNIVERSITY OF WASHINGTON
AND THAT THE LICENSING OF ANY THIRD PARTY'S INTERESTS IN THE ANNEXIN LICENSED
PATENTS SHALL BE THE RESPONSIBILITY AND EXPENSE OF THESEUS AND SUBJECT TO THE
APPROVAL OF NEORX IF NEORX HAS AN OPTION FROM SUCH THIRD PARTY.

                    VII. PATENT MAINTENANCE AND INFRINGEMENT

     7.01 NEORX shall, at its discretion, be responsible for all activities and
expenses with respect to maintaining and/or prosecuting the Linker Licensed
Patents throughout the world, including, but not limited to, USPTO
interferences, patent reexaminations, reissues, abandonment and any other patent
actions.

     7.02 Subject to the rights of any NEORX licensor, NEORX shall, at its
discretion, be responsible for all activities with respect to maintaining and/or
prosecuting the Annexin Licensed Patents throughout the world; provided,
however, that NEORX shall keep THESEUS informed of such activities, conferring
with THESEUS upon request, and THESEUS shall promptly reimburse NEORX for all
expenses with respect to maintaining and/or prosecuting the Annexin Licensed
Patents.

     7.03 Each party shall promptly notify the other party if it becomes aware
of any infringement of a Linker Licensed Patent or Annexin Licensed Patent by a
third party making, using or selling a product in the Field in the Licensed
Territory that is competitive with a Licensed Product of THESEUS then in
clinical trials or being sold and shall provide the other party with available
evidence of such infringement. In the event of such infringement and subject to
the rights of another NEORX licensee or licensor, THESEUS and, in the case of
the Linker Licensed Patents, NEORX's other licensees shall have the right, but
not the obligation, to bring any appropriate suit or action against the
infringer based on any claim of a patent licensed hereunder that specifically
covers the Licensed Product. The costs of any such action brought by THESEUS
shall be borne entirely by THESEUS and NEORX's other licensees, as they may
agree. If they are successful in abating the infringement, the parties bringing
the action shall retain any amount recovered from the infringer, whether by
judgment, award, decree or settlement. If they do not bring a suit or action
within ninety (90) days of written notice of such infringement, NEORX shall have
the right, but not the obligation, to bring any action, at its expense, against
the alleged infringer and retain any amount recovered from the infringer,
whether by judgment, award, decree or settlement.

                                      -8-
<PAGE>

           [*] CONFIDENTIAL TREATMENT REQUESTED. THE REDACTED MATERIAL
                 HAS BEEN FILED SEPARATELY WITH THE COMMISSION.

                               VIII. MISCELLANEOUS

     8.01 THESEUS may not assign or otherwise transfer this Agreement without
the written consent of NEORX, except that THESEUS shall be the right to
sublicense in accordance with Article II and to assign this Agreement in its
entirety to the surviving entity or acquirer in the case of a merger or
acquisition of THESEUS if the surviving entity or acquirer agrees in writing to
be bound by the terms of this Agreement. And any attempted assignment or
transfer not in accordance with this Section 8.01 shall be null and void.

     8.02 All information provided under this Agreement shall be subject to the
existing two-way Confidentiality Agreement dated October 15, 1997 between the
parties except that the obligations thereunder shall extend for five (5) years
past the expiration or termination of this Agreement and the parties shall not
be obligated to return Proprietary Information (as defined therein).

     8.03 Any notice or other written statement required or permitted to be
given by the terms of this Agreement shall be deemed to have been duly make or
given upon mailing thereof from the United States by prepaid registered or
certified mail addressed to the other party at its address set forth below or
such other address as may be designated in writing by such other party.

     TO:      NEORX CORPORATION
              410 West Harrison Street
              Seattle, WA 98119
              Attention:  President

     TO:      THESEUS, LTD.
              One Financial Center
              Boston, MA 02111
              Attention:  Allan M. Green

     8.04 This Agreement represents the entire understanding between the parties
and any amendments or modifications thereof shall be effective only if expressed
in a writing executed by both parties. This Agreement has been submitted to the
scrutiny of both parties and their counsel and shall be given a fair and
reasonable interpretation in accordance with the words hereof, without
consideration or weight being given to its being drafted, in whole or in part,
by or for one of the parties.

     8.05 This Agreement is made on the basis of mutual confidence, and it is
understood that the differences, if any, during the life of this Agreement
should be freely discussed between the parties and solved in an amicable way.
Disputes regarding interpretation, understanding or performance of this
Agreement that cannot be solved by discussions between the parties, shall be
settled in the Courts of the State of Washington (as to which each party hereby
consents to jurisdiction and venue), with each party paying its own expenses.

     8.06 THESEUS shall indemnify, defend and hold harmless NEORX from and
against all third party costs, claims, suits, expenses (including reasonable
attorneys' fees) and damages arising out of or resulting from any act or
omission by THESEUS relating to exercise of its rights and licenses under this
Agreement, including the making, using or selling of Licensed Products, provided
that NEORX gives reasonable notice to THESEUS of any such claims or action,
tenders the defense of such claim or action to THESEUS and assists THESEUS at
THESEUS' expense in defending such claim or action and does not compromise or
settle such claim or action without THESEUS' prior written consent. If, based on
a written opinion of legal counsel provided to NEORX and THESEUS, NEORX
determines that THESEUS is not providing an adequate defense of any matter with
respect to which THESEUS is obligated to defend and indemnify NEORX hereunder or
if representation of both NEORX and THESEUS by the same counsel presents an
actual or potential conflict of interest for the counsel, NEORX shall have the
right to engage counsel of its choice to defend such action, and THESEUS shall
reimburse NEORX for the costs and expenses (including reasonable attorneys'
fees) of such defense.

                                      -9-
<PAGE>

           [*] CONFIDENTIAL TREATMENT REQUESTED. THE REDACTED MATERIAL
                 HAS BEEN FILED SEPARATELY WITH THE COMMISSION.

     8.07 All payments hereunder shall be in U.S. dollars and paid to NEORX at
its principal place of business from a location in the United States, without
any deduction or withholding for or on account of any tax. All payments
hereunder are not creditable against any other payments due hereunder (e.g., not
creditable against royalties) unless expressly stated. Any past due payments
under this Agreement, except as provided in Section 3.01(e), shall accrue
interest at the "prime rate" of interest as quoted by THE WALL STREET JOURNAL
(WESTERN EDITION) (or if not published, another appropriate publication) for the
first business day of each month, plus four percent (4%) or the maximum rate
permitted by applicable law, whichever is less.

     8.08 The parties hereunder are independent contractors and their
relationship shall not constitute a partnership, joint venture or agency.
Neither THESEUS nor NEORX shall have authority to make any statements,
representations or commitments of any kind, or to take any action, that shall be
binding on the other part, without the prior written consent of the party to be
bound.

     8.09 THESEUS shall not export from the United States or reexport from any
country, or permit a third party to export or reexport, a technology or
technical information received under this Agreement to a country where such
export or reexpeort would be in violation of the U.S. Export Administration
Regulations.

     8.10 This Agreement may be executed in two or more counterparts, each of
which shall be deemed an original, but all of which together shall constitute
one and the same instrument.

     8.11 This Agreement shall be governed by and construed in accordance with
the laws of the State of Washington.

     8.12 THESEUS shall keep the terms of this Agreement confidential. In the
event legal counsel to THESEUS reasonably concludes that a copy of this
Agreement needs to be filed with the Securities and Exchange Commission, THESEUS
shall confer with NEORX and request confidential treatment of such portions of
this Agreement as NEORX may reasonably request.

     8.13 Unless otherwise agreed in writing by the parties, neither party
shall, without the prior written consent of the other part (which consent shall
not be unreasonably withheld or delayed), originate any publicity, news release
or public announcement, written or oral, whether to the public or the press,
relating to this Agreement or any amendment hereto, except only such
announcement as is required by law in the opinion of counsel for the party
intending to make such announcement. Any announcement shall be factual and shall
be provided in writing to the other party at least five (5) business days in
advance, where possible, so that the other party may have an opportunity to
comment on the announcement.

     IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be
duly executed in duplicate by their authorized representative.

NEORX CORPORATION                           THESEUS, LTD.

By: /s/Richard L. Anderson                  By: /s/Robert Bender
   -----------------------------------        ----------------------
    Richard L. Anderson                       R. Bender
    Vice President & CFO                      Vice President and Director

                                      -10-
<PAGE>

           [*] CONFIDENTIAL TREATMENT REQUESTED. THE REDACTED MATERIAL
                 HAS BEEN FILED SEPARATELY WITH THE COMMISSION.

                              SCHEDULE A - THESEUS
                       LINKER PATENT SCHEDULE - LINEAGE 1

<TABLE>
<CAPTION>

   WRX REF #             SERIAL #    FILING DATE     ISSUE DATE      PATENT #
   ---------             --------    -----------     ----------      --------
<S>                  <C>            <C>            <C>             <C>
WRX 00001 CCP            065,011       1987/06/19     1990/01/30     4,897,225

WRX 00001 DCP            065,017       1987/06/19     1992/12/29     5,175,343

WRX 00001 GDV            423,180       1989/10/18     1991/08/06     5,037,630

WRX 00001 HDV            576,343       1990/08/31     1993/09/07     5,242,679

WRX 00001 JDV            650,834       1991/02/04     1992/04/09     5,120,526

WRX 00001 JCP            090,609       1993/07/12     1996/09/17     5,556,982

WRX 00001 KPC            PCI/US94/0    1994/07/12
                         7732

WRX 00001 LCO            679,072       1996/07/12     1998/05/26     5,756,685

WRX 00001 HCO            083,902       1998/05/22

WRX 00001 CA1            499,428       1986/01/13     1995/06/27     1,336,076

WRX 00001 CA2            2,165,537     1994/07/12
                                       PCT

WRX 00001 EP1            86100360.6    1986/01/13     1991/08/21     0 168 256 81

WRX 00001 EP2            94923409.0    1994/07/12
                                       PCT

WRX 00001 JP1            61-6155       1986/01/14     1995/07/10     1,947,602

WRX 00001 JP2            4-290223      1992/10/28     1996/09/18     2092986

</TABLE>

<TABLE>
<CAPTION>

   WRX REF #                                        TITLE                                  STATUS         EP ENTRY
   ---------                                        -----                                  ------         --------
<S>                    <C>                                                               <C>             <C>
WRX 00001 CCP             METAL RADIONUCLIDE LABELED PROTEINS FOR DIAGNOSIS AND THERAPY   ISSUED

WRX 00001 DCP             METAL RADIONUCLIDE LABELED PROTEINS FOR DIAGNOSIS AND THERAPY   ISSUED

WRX 00001 GDV             METAL RADIONUCLIDE LABELED PROTEINS FOR DIAGNOSIS AND THERAPY   ISSUED

WRX 00001 HDV             METAL RADIONUCLIDE LABELED PROTEINS FOR DIAGNOSIS AND THERAPY   ISSUED

WRX 00001 JDV             METHOD OF PRODUCING METAL RADIONUCLIDE LABELED PROTEINS FOR     ISSUED
                          DIAGNOSIS AND THERAPY

WRX 00001 JCP             METAL RADIONUCLIDE LABELED PROTEINS FOR DIAGNOSIS AND THERAPY   ISSUED

WRX 00001 KPC             METAL RADIONUCLIDE LABELED PROTEINS FOR DIAGNOSIS AND THERAPY   NATIONAL
                                                                                          PHASE

WRX 00001 LCO             METAL RADIONUCLIDE LABELED PROTEINS, LIGANDS AND ANTI-LIGANDS   ISSUED
                          FOR DIAGNOSIS AND THERAPY

WRX 00001 HCO             METAL RADIONUCLIDE LABELED PROTEINS, LIGANDS AND ANTI-LIGANDS   PENDING
                          FOR DIAGNOSIS AND THERAPY

WRX 00001 CA1             METAL RADIONUCLIDE LABELED PROTEINS FOR DIAGNOSIS AND THERAPY   ISSUED

WRX 00001 CA2             METAL RADIONUCLIDE LABELED PROTEINS FOR DIAGNOSIS AND THERAPY   PENDING

WRX 00001 EP1             METAL RADIONUCLIDE LABELED PROTEINS FOR DIAGNOSIS AND THERAPY   ISSUED         AT BE FR SE
                                                                                                         HO CH L LI LO
                                                                                                         DE IF GI

WRX 00001 EP2             METAL RADIONUCLIDE LABELED PROTEINS FOR DIAGNOSIS AND THERAPY   PENDING

WRX 00001 JP1             METAL RADIONUCLIDE LABELED PROTEINS FOR DIAGNOSIS AND THERAPY   ISSUED

WRX 00001 JP2             METAL RADIONUCLIDE LABELED PROTEINS FOR DIAGNOSIS AND THERAPY   ISSUED

</TABLE>

<PAGE>

           [*] CONFIDENTIAL TREATMENT REQUESTED. THE REDACTED MATERIAL
                 HAS BEEN FILED SEPARATELY WITH THE COMMISSION.

                              SCHEDULE A - THESEUS
                       LINKER PATENT SCHEDULE - LINEAGE 2

<TABLE>
<CAPTION>

       WRX REF #           SERIAL #     FILING DATE    ISSUE DATE      PATENT #
       ---------           --------     -----------    ----------      --------
<S>                   <C>            <C>             <C>           <C>
WRX 00002 OCD            137,952       1987/12/23     1991/09/03     5,045,303

WRX 00002 ECO            338,497       1989/04/13     1989/12/05     4,885,153

WRX 00002 GCO            627,806       1990/12/12     1993/05/25     5,213,787

WRX 00002 MCO            764,001       1991/09/23     1997/03/11     5,609,848

WRX 00002 EP 1           86303757.8    1986/05/16     1993/03/24     EP 0 203 764

WRX 00002 JP 1           1986-         1986/06/13
                         136,324

</TABLE>

<TABLE>
<CAPTION>

       WRX REF #                                       TITLE                                  STATUS         EP ENTRY
       ---------                                       -----                                  ------         --------
<S>                       <C>                                                            <C>                <C>
WRX 00002 OCD              RADIOHOLOGENATED SMALL MOLCULES FOR PROTEIN LABELING            ISSUED

WRX 00002 ECO              RADIOHOLOGENATED PROTEIN                                        ISSUED

WRX 00002 GCO              RADIOHOLOGENATED SMALL MOLCULES FOR PROTEIN LABELING            ISSUED

WRX 00002 MCO              RADIOHOLOGENATED SMALL MOLCULES FOR PROTEIN LABELING            ISSUED

WRX 00002 EP 1             RADIOHOLOGENATED SMALL MOLCULES FOR PROTEIN LABELING            ISSUED

WRX 00002 JP 1             RADIOHOLOGENATED SMALL MOLCULES FOR PROTEIN LABELING            PENDING

</TABLE>

<PAGE>

           [*] CONFIDENTIAL TREATMENT REQUESTED. THE REDACTED MATERIAL
                 HAS BEEN FILED SEPARATELY WITH THE COMMISSION.

                              SCHEDULE A - THESEUS
                       LINKER PATENT SCHEDULE - LINEAGE 7

<TABLE>
<CAPTION>

     WRX REF #           SERIAL #     FILING DATE    ISSUE DATE      PATENT #
     ---------           --------     -----------    ----------      --------
<S>                   <C>            <C>             <C>            <C>
WRX 00007 APA            838,992        1986/03/12    1989/10/31     4,877,868

WRX 00007-CA 1           530,263-3      1987/02/20    1991/02/19     1,280,365

WRX 00007-EP 1           87300426-1     1987/01/19    1996/09/04     0237150

WRX 00007-JP 1           62-54296       1987/03/11    1996/03/19     2,030732

</TABLE>

<TABLE>
<CAPTION>

     WRX REF #                                    TITLE               STATUS         EP ENTRY
     ---------                                    -----               ------         --------
<S>                   <C>                                           <C>            <C>
WRX 00007 APA           RADIONUCLIDE ANITBODY COUPLING               ISSUED

WRX 00007-CA 1          IMPROVED RADIONUCLIDE ANTIBODY COUPLING      ISSUED

WRX 00007-EP 1          IMPROVED RADIONUCLIDE ANTIBODY COUPLING      ISSUED          FR DE IT GB

WRX 00007-JP 1          IMPROVED RADIONUCLIDE ANTIBODY COUPLING      ISSUED

</TABLE>

<PAGE>

           [*] CONFIDENTIAL TREATMENT REQUESTED. THE REDACTED MATERIAL
                 HAS BEEN FILED SEPARATELY WITH THE COMMISSION.

                              SCHEDULE A - THESEUS
                       LINKER PATENT SCHEDULE - LINEAGE 12

<TABLE>
<CAPTION>

     WRX REF #           SERIAL #     FILING DATE    ISSUE DATE      PATENT #
     ---------           --------     -----------    ----------      --------
<S>                    <C>           <C>            <C>            <C>
WRX 80012 BDP            172,804        1988/03/23    1990/10/23     4,965,392

WRX 80012 DBV            494,191        1990/03/15    1992/02/25     5,091,514

WRX 80012 FCO            075,305        1993/06/11    1997/10/28     5,681,927

WRX 80012 HCO            434,961        1995/05/08    1997/04/01     5,616,692

WRX 80012 AU1            13751/88       1988/03/25    1988/03/25     617938

WRX 80012 CA1            562,452        1988/03/25    1994/03/29     1,328,147

WRX 80012 EP1            88104755.9     1988/03/24    1994/05/08     0 284 071 81

</TABLE>

<TABLE>
<CAPTION>

     WRX REF #                                   TITLE                                  STATUS         EP ENTRY
     ---------                                   -----                                  ------         --------
<S>                  <C>                                                              <C>             <C>
WRX 80012 BDP          CHELATING COMPOUNDS FOR METAL-RADIONUCLIDE LABELED PROTEINS     ISSUED

WRX 80012 DBV          METAL-RADIONUCLIDE-LABELED PROTEINS AND GLYCOPROTIENS FOR       ISSUED
                       DIAGNOSIS AND THERAPY

WRX 80012 FCO          METAL-RADIONUCLIDE-LABELED PROTEINS AND GLYCOPROTIENS FOR       ISSUED
                       DIAGNOSIS AND THERAPY

WRX 80012 HCO          METAL-RADIONUCLIDE-LABELED PROTEINS AND GLYCOPROTIENS FOR       ISSUED
                       DIAGNOSIS AND THERAPY

WRX 80012 AU1          METAL-RADIONUCLIDE-LABELED PROTEINS AND GLYCOPROTIENS FOR       ISSUED
                       DIAGNOSIS AND THERAPY

WRX 80012 CA1          METAL-RADIONUCLIDE-LABELED PROTEINS AND GLYCOPROTIENS FOR       ISSUED
                       DIAGNOSIS AND THERAPY

WRX 80012 EP1          METAL-RADIONUCLIDE-LABELED PROTEINS AND GLYCOPROTIENS FOR       ISSUED
                       DIAGNOSIS AND THERAPY
</TABLE>

<PAGE>

           [*] CONFIDENTIAL TREATMENT REQUESTED. THE REDACTED MATERIAL
                 HAS BEEN FILED SEPARATELY WITH THE COMMISSION.

                              SCHEDULE A - THESEUS
                       LINKER PATENT SCHEDULE - LINEAGE 14

<TABLE>
<CAPTION>

     WRX REF #           SERIAL #     FILING DATE    ISSUE DATE      PATENT #
     ---------           --------     -----------    ----------      --------
<S>                  <C>             <C>            <C>            <C>
WRX 00012 BCP            172,004        1988/03/23    1990/10/23     4,965,392

WRX 00012 DDV            494,191        1990/03/13    1992/02/25     5,091,514

WRX 00012 FOO            075,305        1993/06/11    1997/10/28     5,681,927

WRX 00012 HCO            436,961        1995/05/06    1997/04/01     5,616,692

WRX 00012-AU1            13751/88       1988/03/25    1988/03/25     619738

WRX 00012-CA1            562,452        1988/03/25    1994/03/29     1,328,147

WRX 00012-EP1            88104755.9     1988/03/24    1994/06/08     0 284 071 81

</TABLE>

<TABLE>
<CAPTION>

     WRX REF #                                    TITLE                                  STATUS         EP ENTRY
     ---------                                    -----                                  ------         --------
<S>                   <C>                                                              <C>             <C>
WRX 00012 BCP           CHELATING COMPOUNDS FOR METAL-RADIONUCLIDE LABELED PROTEINS     ISSUED

WRX 00012 DDV           METAL-RADIONUCLIDE-LABELED PROTEINS AND GLYCOPROTEINS FOR       ISSUED
                        DIAGNOSIS AND THERAPY

WRX 00012 FOO           METAL-RADIONUCLIDE-LABELED PROTEINS AND GLYCOPROTEINS FOR       ISSUED
                        DIAGNOSIS AND THERAPY

WRX 00012 HCO           METAL-RADIONUCLIDE-LABELED PROTEINS AND GLYCOPROTEINS FOR       ISSUED
                        DIAGNOSIS AND THERAPY

WRX 00012-AU1           METAL-RADIONUCLIDE-LABELED PROTEINS AND GLYCOPROTEINS FOR       ISSUED
                        DIAGNOSIS AND THERAPY

WRX 00012-CA1           METAL-RADIONUCLIDE-LABELED PROTEINS AND GLYCOPROTEINS FOR       ISSUED         AT BE FR DE
                        DIAGNOSIS AND THERAPY                                                          NE IT LU SE
                                                                                                       CH GB

WRX 00012-EP1           METAL-RADIONUCLIDE-LABELED PROTEINS AND GLYCOPROTEINS FOR       ISSUED         FR DE IT GB
                        DIAGNOSIS AND THERAPY

</TABLE>

<PAGE>

           [*] CONFIDENTIAL TREATMENT REQUESTED. THE REDACTED MATERIAL
                 HAS BEEN FILED SEPARATELY WITH THE COMMISSION.

                              SCHEDULE A - THESEUS
                       LINKER PATENT SCHEDULE - LINEAGE 20

<TABLE>
<CAPTION>

     WRX REF #           SERIAL #     FILING DATE    ISSUE DATE      PATENT #
     ---------           --------     -----------    ----------      --------
<S>                    <C>           <C>            <C>             <C>
WRX 00020 APA            157,284        1988/02/17    1993/04/13     5,202,451

WRX 00020 OCO            532,041        1995/09/21    1997/02/25     5,608,028

</TABLE>

<TABLE>

     WRX REF #                                   TITLE                      STATUS         EP ENTRY
     ---------                                   -----                      ------         --------
<S>                  <C>                                                  <C>             <C>
WRX 00020 APA          ARCHIMERIC RADIOMETAL CHELATING COMPOUNDS           ISSUED

WRX 00020 OCO          ARCHIMERIC RADIOMETAL CHELATING COMPOUNDS           ISSUED

</TABLE>

<PAGE>

           [*] CONFIDENTIAL TREATMENT REQUESTED. THE REDACTED MATERIAL
                 HAS BEEN FILED SEPARATELY WITH THE COMMISSION.

                              SCHEDULE A - THESEUS
                       LINKER PATENT SCHEDULE - LINEAGE 26
<TABLE>
<CAPTION>

     WRX REF #           SERIAL #     FILING DATE    ISSUE DATE      PATENT #
     ---------           --------     -----------    ----------      --------
<S>                  <C>            <C>             <C>             <C>
WRX 00026 APA            178,418        1988/04/06    1991/10/15     5,057,301

</TABLE>

<TABLE>
<CAPTION>

     WRX REF #                                   TITLE                                  STATUS         EP ENTRY
     ---------                                   -----                                  ------         --------
<S>                   <C>                                                             <C>             <C>
WRX 00026 APA          MODIFIED CELLULAR SUBSTRATES USED AS LINKERS FOR INCREASED      ISSUED
                       DELL RETENTION OF DIAGNOSTIC AND THERAPEUTIC AGENTS

</TABLE>

<PAGE>

           [*] CONFIDENTIAL TREATMENT REQUESTED. THE REDACTED MATERIAL
                 HAS BEEN FILED SEPARATELY WITH THE COMMISSION.

                              SCHEDULE A - THESEUS
                       LINKER PATENT SCHEDULE - LINEAGE 28

<TABLE>
<CAPTION>

     WRX REF #           SERIAL #     FILING DATE    ISSUE DATE      PATENT #
     ---------           --------     -----------    ----------      --------
<S>                     <C>          <C>            <C>            <C>
WRX 00028 APA            187,714        1988/04/29    1991/10/22     5,059,541

WRX 00028-EP1            89107823 0     1989/04/28    1996/01/03     339 684 81

</TABLE>

<TABLE>
<CAPTION>

     WRX REF #                        TITLE                        STATUS         EP ENTRY
     ---------                        -----                        ------         --------
<S>                  <C>                                         <C>
WRX 00028 APA          MINIMAL DERIVATIZATION OF PROTEINS          ISSUED

WRX 00028-EP1          MINIMAL DERIVATIZATION OF PROTEINS          ISSUED         FR DE IT GB

</TABLE>

<PAGE>

           [*] CONFIDENTIAL TREATMENT REQUESTED. THE REDACTED MATERIAL
                 HAS BEEN FILED SEPARATELY WITH THE COMMISSION.

                              SCHEDULE A - THESEUS
                       LINKER PATENT SCHEDULE - LINEAGE 29

<TABLE>
<CAPTION>

       WRX REF #           SERIAL #     FILING DATE    ISSUE DATE      PATENT #
       ---------           --------     -----------    ----------      --------
<S>                    <C>            <C>            <C>            <C>
WRX 00029 APA            201,134        1988/05/31    1991/01/29     4,988,496

WRX 00029 BDV            589,469        1990/09/27    1991/12/24     5,075,099

WRX 00029 CDV            404,121        1991/12/06    1995/07/25     5,436,352

WRX 00029 DDV            459,414        1995/06/02    1997/04/29     5,625,075

WRX 00029-EP1            89109756.0     1989/05/30    1993/08/11     0 344 724 81

</TABLE>

<TABLE>
<CAPTION>

       WRX REF #                                    TITLE                  STATUS         EP ENTRY
       ---------                                    -----                  ------         --------
<S>                    <C>                                               <C>             <C>
WRX 00029 APA           METAL REDIONUCLIDE CHELATING COMPOUNDS FOR          ISSUED
                        IMPROVED CHELATION KINETICS

WRX 00029 BDV           METAL REDIONUCLIDE CHELATING COMPOUNDS FOR          ISSUED
                        IMPROVED CHELATION KINETICS

WRX 00029 CDV           METAL REDIONUCLIDE CHELATING COMPOUNDS FOR          ISSUED
                        IMPROVED CHELATION KINETICS

WRX 00029 DDV           METAL REDIONUCLIDE CHELATING COMPOUNDS FOR          ISSUED
                        IMPROVED CHELATION KINETICS

WRX 00029-EP1           METAL REDIONUCLIDE CHELATING COMPOUNDS FOR          ISSUED         FR DE IT GB
                        IMPROVED CHELATION KINETICS

</TABLE>

<PAGE>

           [*] CONFIDENTIAL TREATMENT REQUESTED. THE REDACTED MATERIAL
                 HAS BEEN FILED SEPARATELY WITH THE COMMISSION.

                              SCHEDULE A - THESEUS
                       LINKER PATENT SCHEDULE - LINEAGE 32
<TABLE>
<CAPTION>

     WRX REF #           SERIAL #     FILING DATE    ISSUE DATE      PATENT #
     ---------           --------     -----------    ----------      --------
<S>                    <C>           <C>            <C>            <C>
WRX 00032 APA            232,337        1988/08/15    1992/08/04     5,135,736

WRX 00032 DCP            390,241        1989/08/07    1992/12/08     5,169,933

WRX 00032-CA1            608,198        1989/08/11    1995/02/21     1,334,513

WRX 00032-EP1            89250014.1     1989/08/14    1992/12/13     E 0 359 347

</TABLE>

<TABLE>
<CAPTION>

     WRX REF #                                   TITLE                                  STATUS         EP ENTRY
     ---------                                   -----                                  ------         --------
<S>                  <C>                                                            <C>               <C>
WRX 00032 APA          COVALENTLY-LINKED COMPLEXES AND METHOD FOR ENHANCED             ISSUED
                       CYTOTOXICITY AND IMAGING

WRX 00032 DCP          COVALENTLY-LINKED COMPLEXES AND METHOD FOR ENHANCED             ISSUED
                       CYTOTOXICITY AND IMAGING

WRX 00032-CA1          COVALENTLY-LINKED COMPLEXES AND METHOD FOR ENHANCED             ISSUED
                       CYTOTOXICITY AND IMAGING

WRX 00032-EP1          COVALENTLY-LINKED COMPLEXES AND METHOD FOR ENHANCED             ISSUED         FR DE IT GB
                       CYTOTOXICITY AND IMAGING

</TABLE>

<PAGE>

           [*] CONFIDENTIAL TREATMENT REQUESTED. THE REDACTED MATERIAL
                 HAS BEEN FILED SEPARATELY WITH THE COMMISSION.

                              SCHEDULE A - THESEUS
                       LINKER PATENT SCHEDULE - LINEAGE 35

<TABLE>
<CAPTION>

     WRX REF #           SERIAL #     FILING DATE    ISSUE DATE      PATENT #
     ---------           --------     -----------    ----------      --------
<S>                    <C>            <C>           <C>             <C>
WRX 00035 BPC            PCT/US89/04    1989/09/29
                         266

WRX 00035 CCD            830,973        1992/02/10    1992/12/15     5,171,563

WRX 00035-EP1            89912052.1     1989/09/29    1994/11/09     EP 0 436 664

</TABLE>

<TABLE>
<CAPTION>

     WRX REF #                                 TITLE                                  STATUS         EP ENTRY
     ---------                                 -----                                  ------         --------
<S>                 <C>                                                            <C>              <C>
WRX 00035 BPC        CLEAVABLE LINKERS FOR THE REDUCTION OF NON-TARGET ORGAN         NATIONAL
                     RETENTION OF IMMUNOCONJUGATES                                   PHASE

WRX 00035 CCD        CLEAVABLE LINKERS FOR THE REDUCTION OF NON-TARGET ORGAN         ISSUED
                     RETENTION OF IMMUNOCONJUGATES

WRX 00035-EP1        CLEAVABLE LINKERS FOR THE REDUCTION OF NON-TARGET ORGAN         ISSUED         FR DE GB
                     RETENTION OF IMMUNOCONJUGATES

</TABLE>

<PAGE>

           [*] CONFIDENTIAL TREATMENT REQUESTED. THE REDACTED MATERIAL
                 HAS BEEN FILED SEPARATELY WITH THE COMMISSION.

                              SCHEDULE A - THESEUS
                       LINKER PATENT SCHEDULE - LINEAGE 37

<TABLE>
<CAPTION>

     WRX REF #           SERIAL #     FILING DATE    ISSUE DATE      PATENT #
     ---------           --------     -----------    ----------      --------
<S>                     <C>          <C>            <C>            <C>
WRX 00037 BCP            415,154        1989/09/29    1991/11/19     5,066,789

WRX 00037 OPC            PCT/US89/04267 1989/09/29

WRX 00037 HCO            332,045        1994/11/01    1997/05/27     5,633,351

WRX 00037 ICO            342,789        1994/11/21    1996/05/28     5,521,290

WRX 00037 JDV            648,833        1996/05/16

WRX 00037-EP1            89911718.8     1989/09/29    1995/11/08     0 434 765

WRX 00037-JP1            510891/89      1989/09/29

</TABLE>

<TABLE>
<CAPTION>

     WRX REF #                                 TITLE                                  STATUS          EP ENTRY
     ---------                                 -----                                  ------          --------
<S>                  <C>                                                           <C>               <C>
WRX 00037 BCP         TARGETING PROTEIN-DIAGNOSTIC/THERAPEUTIC AGENT CONJUGATES     ISSUED
                      HAVING SCHIFF BASE LINKAGES

WRX 00037 OPC         TARGETING PROTEIN-DIAGNOSTIC/THERAPEUTIC AGENT CONJUGATES     NATIONAL PHASE
                      HAVING SCHIFF BASE LINKAGES

WRX 00037 HCO         TARGETING PROTEIN-DIAGNOSTIC/THERAPEUTIC AGENT CONJUGATES     ISSUED
                      HAVING SCHIFF BASE LINKAGES

WRX 00037 ICO         TARGETING PROTEIN-DIAGNOSTIC/THERAPEUTIC AGENT CONJUGATES     ISSUED
                      HAVING SCHIFF BASE LINKAGES

WRX 00037 JDV         TARGETING PROTEIN-DIAGNOSTIC/THERAPEUTIC AGENT CONJUGATES     ALLOWED
                      HAVING SCHIFF BASE LINKAGES

WRX 00037-EP1         TARGETING PROTEIN-DIAGNOSTIC/THERAPEUTIC AGENT CONJUGATES     ISSUED           FR DE GB
                      HAVING SCHIFF BASE LINKAGES

WRX 00037-JP1         TARGETING PROTEIN-DIAGNOSTIC/THERAPEUTIC AGENT CONJUGATES     PUBLISHED
                      HAVING SCHIFF BASE LINKAGES

</TABLE>

<PAGE>

         [*] CONFIDENTIAL TREATMENT REQUESTED. THE REDACTED MATERIAL HAS
                   BEEN FILED SEPARATELY WITH THE COMMISSION.

                              SCHEDULE A - THESEUS
                       LINKER PATENT SCHEDULE - LINEAGE 44

<TABLE>
<CAPTION>

     WRX REF #           SERIAL #     FILING DATE    ISSUE DATE      PATENT #
     ---------           --------     -----------    ----------      --------
<S>                     <C>          <C>             <C>            <C>
WRX 00044 CCD            018,482        1993/02/16    1995/02/21     5,391,723

</TABLE>

<TABLE>
<CAPTION>

     WRX REF #                     TITLE                          STATUS         EP ENTRY
     ---------                     -----                          ------         --------
<S>                   <C>                                       <C>             <C>
WRX 00044 CCD          OLIGONUCLEOTIDE CONJUGATES                 ISSUED

</TABLE>

<PAGE>

           [*] CONFIDENTIAL TREATMENT REQUESTED. THE REDACTED MATERIAL
                 HAS BEEN FILED SEPARATELY WITH THE COMMISSION.

                              SCHEDULE A - THESEUS
                       LINKER PATENT SCHEDULE - LINEAGE 45

<TABLE>
<CAPTION>

     WRX REF #           SERIAL #     FILING DATE    ISSUE DATE      PATENT #
     ---------           --------     -----------    ----------      --------
<S>                     <C>          <C>             <C>             <C>
WRX 00045 OCP            454,295        1989/12/19    1991/05/21     5,017,693

WRX 00045 DDV            678,535        1991/03/29    1992/08/25     5,141,648

WRX 00045 FCO            242,702        1994/05/13    1996/10/08     5,563,250

</TABLE>

<TABLE>
<CAPTION>

     WRX REF #                                   TITLE                                  STATUS         EP ENTRY
     ---------                                   -----                                  ------         --------
<S>                  <C>                                                              <C>             <C>
WRX 00045 OCP          CLEAVABLE CONJUGATES FOR THE DELIVERY AND RELEASE OF AGENTS     ISSUED
                       IN NATIVE FORM

WRX 00045 DDV          METHODS FOR ISOLATING COMPOUNDS USING CLEAVABLE LINKER BOUND    ISSUED
                       MATRICES

WRX 00045 FCO          CLEAVABLE CONJUGATES FOR THE DELIVERY AND RELEASE OF AGENTS     ISSUED
                       IN NATIVE FORM
</TABLE>

<PAGE>

           [*] CONFIDENTIAL TREATMENT REQUESTED. THE REDACTED MATERIAL
                 HAS BEEN FILED SEPARATELY WITH THE COMMISSION.

                              SCHEDULE A - THESEUS
                       LINKER PATENT SCHEDULE - LINEAGE 47

<TABLE>
<CAPTION>

     WRX REF #           SERIAL #      FILING DATE    ISSUE DATE      PATENT #
     ---------           --------      -----------    ----------      --------
<S>                   <C>             <C>            <C>             <C>
WRX 00047 BPC            PCT/US90/03    1990/06/15
                         425

WRX 00047 CCP            577,959        1990/09/05    1992/11/17     5,164,176

WRX 00047 DDV            973,048        1992/11/06    1993/10/05     5,250,666

WRX 00047 FPC            PCT/US94/07    1994/07/12
                         733

WRX 00047 GUS            591,560        1994/07/12
                                        PCT

WRX 00047-AU1            59567/90       1990/06/15    1994/07/13     AU 645258

WRX 00047-CA1            2,031,528      1990/06/15    1997/03/18     2,031,528
                                        (PCT
                                        FILING DT)

WRX 00047-CA2            2,165,052      1994/07/12
                                        PCI

WRX 00047-EP1            90911153.6     1990/06/15    1995/11/15     0 431 146 81

WRX 00047-EP2            94924458.6     1994/07/12
                                        PCT

WRX 00047-JP1            2-510108       1990/06/15

</TABLE>

<TABLE>
<CAPTION>

     WRX REF #                                 TITLE                                  STATUS          EP ENTRY
     ---------                                 -----                                  ------          --------
<S>                <C>                                                           <C>                 <C>
WRX 00047 BPC        RADIONUCLIDE METAL CHELATES FOR THE RADIOLABELING OF          NATIONAL PHASE
                     PROTEINS

WRX 00047 CCP        RADIONUCLIDE METAL CHELATES FOR THE RADIOLABELING OF          ISSUED
                     PROTEINS

WRX 00047 DDV        RADIONUCLIDE METAL CHELATES FOR THE RADIOLABELING OF          ISSUED
                     PROTEINS

WRX 00047 FPC        RADIONUCLIDE METAL CHELATES FOR THE RADIOLABELING OF          NATIONAL PHASE
                     LIGANDS, ANTI-LIGANDS OR OTHER PROTEINS

WRX 00047 GUS        RADIONUCLIDE METAL CHELATES FOR THE RADIOLABELING OF          ALLOWED
                     LIGANDS, ANTI-LIGANDS OR OTHER PROTEINS

WRX 00047-AU1        RADIONUCLIDE METAL CHELATES FOR THE RADIOLABELING OF          ISSUED
                     PROTEINS

WRX 00047-CA1        RADIONUCLIDE METAL CHELATES FOR THE RADIOLABELING OF          ISSUED
                     PROTEINS

WRX 00047-CA2        RADIONUCLIDE METAL CHELATES FOR THE RADIOLABELING OF          PENDING
                     LIGANDS, ANTI-LIGANDS OR OTHER PROTEINS

WRX 00047-EP1        RADIONUCLIDE METAL CHELATES FOR THE RADIOLABELING OF          ISSUED           FR DE IT GB
                     PROTEINS

WRX 00047-EP2        RADIONUCLIDE METAL CHELATES FOR THE RADIOLABELING OF          PENDING
                     LIGANDS, ANTI-LIGANDS OR OTHER PROTEINS

WRX 00047-JP1        RADIONUCLIDE METAL CHELATES FOR THE RADIOLABELING OF          PUBLISHED
                     PROTEINS

</TABLE>

<PAGE>

           [*] CONFIDENTIAL TREATMENT REQUESTED. THE REDACTED MATERIAL
                 HAS BEEN FILED SEPARATELY WITH THE COMMISSION.

                              SCHEDULE A - THESEUS
                       LINKER PATENT SCHEDULE - LINEAGE 48

<TABLE>
<CAPTION>

     WRX REF #           SERIAL #     FILING DATE    ISSUE DATE      PATENT #
     ---------           --------     -----------    ----------      --------
<S>                    <C>           <C>           <C>             <C>
WRX 00048 APA            373,426        1992/06/30    1992/03/10     5,094,848

</TABLE>

<TABLE>
<CAPTION>

     WRX REF #                                TITLE                                  STATUS         EP ENTRY
     ---------                                -----                                  ------         --------
<S>               <C>                                                             <C>              <C>
WRX 00048 APA       CLEAVABLE DIPHOSPHATE AND AMIDATED DIPHOSPHATE LINKERS          ISSUED

</TABLE>

<PAGE>

           [*] CONFIDENTIAL TREATMENT REQUESTED. THE REDACTED MATERIAL
                 HAS BEEN FILED SEPARATELY WITH THE COMMISSION.

                              SCHEDULE A - THESEUS
                       LINKER PATENT SCHEDULE - LINEAGE 55

<TABLE>
<CAPTION>

     WRX REF #     SERIAL #     FILING DATE    ISSUE DATE      PATENT #
     ---------     --------     -----------    ----------      --------
<S>               <C>            <C>           <C>            <C>
WRX 00055 APA      457,480        1989/12/29    1992/05/12     5,112,953

WRX 00055 BPC      PCT/US90/07    1990/12/27
                   595

WRX 00055 CDP      641,158        1991/01/14    1992/12/29     5,175,257

WRX 00055-CA1      2,048,654      1990/12/27

WRX 00055-JP1      3-502908       1990/12/27

</TABLE>

<TABLE>
<CAPTION>

     WRX REF #                                TITLE                          STATUS          EP ENTRY
     ---------                                -----                          ------          --------
<S>                <C>                                                    <C>               <C>
WRX 00055 APA        RADIOLABELED PROTEINS FOR DIAGNOSTIC AND               ISSUED
                     THERAPEUTIC USE

WRX 00055 BPC        RADIOLABELED PROTEINS FOR DIAGNOSTIC AND               NATIONAL PHASE
                     THERAPEUTIC USE

WRX 00055 CDP        RADIOLABELED PROTEINS FOR DIAGNOSTIC AND               ISSUED
                     THERAPEUTIC USE

WRX 00055-CA1        RADIOLABELED PROTEINS FOR DIAGNOSTIC AND               PENDING
                     THERAPEUTIC USE

WRX 00055-JP1        RADIOLABELED PROTEINS FOR DIAGNOSTIC AND               PUBLISHED
                     THERAPEUTIC USE
</TABLE>

<PAGE>

           [*] CONFIDENTIAL TREATMENT REQUESTED. THE REDACTED MATERIAL
                 HAS BEEN FILED SEPARATELY WITH THE COMMISSION.

                              SCHEDULE A - THESEUS
                       LINKER PATENT SCHEDULE - LINEAGE 60
<TABLE>
<CAPTION>

     WRX REF #           SERIAL #      FILING DATE    ISSUE DATE      PATENT #
     ---------           --------      -----------    ----------      --------
<S>                    <C>            <C>            <C>            <C>
WRX 00060 APA            591,104        1990/09/28    1993/10/12     5,252,721

WRX 00060 CPC            PCT/US94/09    1994/08/17
                         292

WRX 00060 DDO            393,882        1995/02/22    1997/11/04     5,684,137

WRX 00060-CA1            2,165,538      1994/08/17
                                        PCT

WRX 00060-EP1            94925919.6     1994/08/17
                                        PCT

</TABLE>

<TABLE>
<CAPTION>

     WRX REF #                                    TITLE                                  STATUS         EP ENTRY
     ---------                                    -----                                  ------         --------
<S>                  <C>                                                              <C>              <C>
WRX 00060 APA          S3W CHELATING COMPOUNDS                                         ISSUED

WRX 00060 CPC          S3W CHELATING COMPOUNDS FOR THE RADIOLABELING OF LIGANDS,       NATIONAL
                       ANTI-LIGANDS OR OTHER PROTEINS                                  PHASE

WRX 00060 DDO          S3W CHELATING COMPOUNDS FOR THE RADIOLABELING OF LIGANDS,       ISSUED
                       ANTI-LIGANDS OR OTHER PROTEINS

WRX 00060-CA1          S3W CHELATING COMPOUNDS FOR THE RADIOLABELING OF LIGANDS,       PENDING
                       ANTI-LIGANDS OR OTHER PROTEINS

WRX 00060-EP1          S3W CHELATING COMPOUNDS FOR THE RADIOLABELING OF LIGANDS,       PENDING        PENDING
                       ANTI-LIGANDS OR OTHER PROTEINS

</TABLE>

<PAGE>

           [*] CONFIDENTIAL TREATMENT REQUESTED. THE REDACTED MATERIAL
                 HAS BEEN FILED SEPARATELY WITH THE COMMISSION.

                              SCHEDULE A - THESEUS
                       LINKER PATENT SCHEDULE - LINEAGE 63

<TABLE>
<CAPTION>

     WRX REF #           SERIAL #      FILING DATE    ISSUE DATE      PATENT #
     ---------           --------      -----------    ----------      --------
<S>                    <C>             <C>            <C>           <C>
WRX 00063 APA            590,180        1990/09/28    1992/12/29     5,175,256

WRX 00063 BDV            994,939        1992/12/22    1995/03/21     5,399,710

</TABLE>

<TABLE>
<CAPTION>

     WRX REF #                  TITLE                    STATUS         EP ENTRY
     ---------                  -----                    ------         --------
<S>                 <C>                                <C>             <C>
WRX 00063 APA         PROTEIN LABELING REAGENTS           ISSUED

WRX 00063 BDV         PROTEIN LABELING REAGENTS           ISSUED

</TABLE>

<PAGE>

           [*] CONFIDENTIAL TREATMENT REQUESTED. THE REDACTED MATERIAL
                 HAS BEEN FILED SEPARATELY WITH THE COMMISSION.

                              SCHEDULE A - THESEUS
                       LINKER PATENT SCHEDULE - LINEAGE 64

<TABLE>
<CAPTION>

    WRX REF #            SERIAL #     FILING DATE    ISSUE DATE      PATENT #
    ---------            --------     -----------    ----------      --------
<S>                  <C>               <C>            <C>           <C>
WRX 00064  CPC          PCI/US91/071    1991/09/27
                        43

WRX 00064 DCO           071,357         1993/06/03    1996/08/27     5,549,683

WRX 00064-CA1           2,077,309       1992/09/01

WRX 00064-EP1           91918218.8      1991/09/27    1997/05/14     0510132

WRX 00064-JP1           324565/1992     1991/09/27

</TABLE>

<TABLE>
<CAPTION>

    WRX REF #                                TITLE                                  STATUS         EP ENTRY
    ---------                                -----                                  ------         --------
<S>             <C>                                                              <C>              <C>
WRX 00064  CPC     CHEMICALLY DEFINED POLYMERIC CARRIERS FOR RELEASE OF            NATIONAL
                   COVALENTLY LINKED AGENTS                                        PHASE

WRX 00064 DCO      CHEMICALLY DEFINED POLYMERIC CARRIERS FOR RELEASE OF            ISSUED
                   COVALENTLY LINKED AGENTS

WRX 00064-CA1      POLYMERIC CARRIERS FOR RELEASE OF COVALENTLY LINKED AGENTS      PENDING

WRX 00064-EP1      CHEMICALLY DEFINED POLYMERIC CARRIERS FOR RELEASE OF            ISSUED         FR DE GB
                   COVALENTLY LINKED AGENTS

WRX 00064-JP1      CHEMICALLY DEFINED POLYMERIC CARRIERS FOR RELEASE OF            PENDING
                   COVALENTLY LINKED AGENTS

</TABLE>

<PAGE>

           [*] CONFIDENTIAL TREATMENT REQUESTED. THE REDACTED MATERIAL
                 HAS BEEN FILED SEPARATELY WITH THE COMMISSION.

                              SCHEDULE A - THESEUS
                       LINKER PATENT SCHEDULE - LINEAGE 74

<TABLE>
<CAPTION>

     WRX REF #           SERIAL #      FILING DATE    ISSUE DATE      PATENT #
     ---------           --------      -----------    ----------      --------
<S>                   <C>             <C>            <C>             <C>
WRX 00074 BPC            PCT/US95/06    1995/05/18
                         522

WRX 00074 CCP            463,232        1995/06/05

WRX 00074-CA1            2,190,727      1995/05/18

WRX 00074-EP1            95922105.0     1995/05/18

WRX 00074-JP1            7-530508       1995/05/18

</TABLE>

<TABLE>
<CAPTION>

     WRX REF #                                    TITLE                                  STATUS         EP ENTRY
     ---------                                    -----                                  ------         --------
<S>                  <C>                                                              <C>              <C>
WRX 00074 BPC          AROMATIC AMINE SUBSTITUTED BRIDGED NITROGEN                      NATIONAL
                       AND SULFUR DONOR ATOM LIGANDS FOR IMAGING                        PHASE

WRX 00074 CCP          AROMATIC AMINE SUBSTITUTED BRIDGED NITROGEN                      PENDING
                       AND SULFUR DONOR ATOM LIGANDS FOR IMAGING

WRX 00074-CA1          AROMATIC AMINE SUBSTITUTED BRIDGED NITROGEN                      PENDING
                       AND SULFUR DONOR ATOM LIGANDS FOR IMAGING

WRX 00074-EP1          AROMATIC AMINE SUBSTITUTED BRIDGED NITROGEN                      PENDING
                       AND SULFUR DONORATOM LIGANDS FOR IMAGING

WRX 00074-JP1          AROMATIC AMINE SUBSTITUTED BRIDGED NITROGEN                      PENDING
                       AND SULFUR DONOR ATOM LIGANDS FOR IMAGING
</TABLE>

<PAGE>

           [*] CONFIDENTIAL TREATMENT REQUESTED. THE REDACTED MATERIAL
                 HAS BEEN FILED SEPARATELY WITH THE COMMISSION.

                              SCHEDULE A - THESEUS
                       LINKER PATENT SCHEDULE - LINEAGE 73
<TABLE>
<CAPTION>

    WRX REF #             SERIAL #     FILING DATE    ISSUE DATE      PATENT #
    ---------             --------     -----------    ----------      --------
<S>                    <C>            <C>            <C>             <C>
WRX 00073 DPC            PCT/US95/00    1995/01/23
                         953

WRX 00073 EPC            PCT/US95/07    1995/06/13
                         599

WRX 00073 FPC            PCT/US95/15    1995/12/06
                         651

WRX 00073 HCP            690,184        1996/07/26

WRX 00073 JCP            PCT/US97/12    1997/07/24
                         977

WRX 00073-CA1            2,180,555      1995/01/23
                                        (PCT)

WRX 00073-CA2            2,185,349      1995/01/23
                                        (PCT)

WRX 00073-CA3            2,206,274      1995/12/06

WRX 00073-EP1            95913955.1     1995/01/23
                                        (PCT)

WRX 00073-EP2            95923885.8     1995/06/13

WRX 00073-EP3            95942562.0     1995/12/06

WRX 00073-JP1            519,734/95     1995/01/23
                                        (PCT)

WRX 00073-JP2            8-502468       1995/06/13
                                        (PCT)

WRX 00073-JP3            8-517741       1995/12/06

</TABLE>

<TABLE>
<CAPTION>

    WRX REF #                              TITLE                                     STATUS          EP ENTRY
    ---------                              -----                                     ------          --------
<S>                <C>                                                         <C>                  <C>
WRX 00073 DPC       RADIOLABELED ANNEXINS                                         NATIONAL PHASE

WRX 00073 EPC       RADIOLABELED ANNEXIN-GALACTOSE CONJUGATES                     NATIONAL PHASE

WRX 00073 FPC       RADIOLABELED ANNEXIN-GALACTOSE CLUSTER CONJUGATES             NATIONAL PHASE

WRX 00073 HCP       RADIOLABELED ANNEXINS                                         PENDING

WRX 00073 JCP       RADIOLABELED ANNEXINS                                         PENDING

WRX 00073-CA1       RADIOLABELED ANNEXINS                                         PENDING

WRX 00073-CA2       RADIOLABELED ANNEXIN-GALACTOSE CONJUGATES                     PENDING

WRX 00073-CA3       RADIOLABELED ANNEXIN-GALACTOSE CLUSTER CONJUGATES             PENDING

WRX 00073-EP1       RADIOLABELED ANNEXINS                                         PENDING

WRX 00073-EP2       RADIOLABELED ANNEXIN-GALACTOSE CONJUGATES                     PENDING

WRX 00073-EP3       RADIOLABELED ANNEXIN-GALACTOSE CLUSTER CONJUGATES             PENDING

WRX 00073-JP1       RADIOLABELED ANNEXINS                                         PUBLISHED

WRX 00073-JP2       RADIOLABELED ANNEXIN-GALACTOSE CONJUGATES                     PENDING

WRX 00073-JP3       RADIOLABELED ANNEXIN-GALACTOSE CLUSTER CONJUGATES             PENDING

</TABLE>

<PAGE>

           [*] CONFIDENTIAL TREATMENT REQUESTED. THE REDACTED MATERIAL
                 HAS BEEN FILED SEPARATELY WITH THE COMMISSION.

                              SCHEDULE A - THESEUS
                       LINKER PATENT SCHEDULE - LINEAGE 73
                                   SCHEDULE C

                            LINKER LICENSED PRODUCTS

None currently.

<PAGE>

           [*] CONFIDENTIAL TREATMENT REQUESTED. THE REDACTED MATERIAL
                 HAS BEEN FILED SEPARATELY WITH THE COMMISSION.

     ADDENDUM TO NEORX THESEUS AGREEMENT: COLLABORATIVE RESEARCH ACTIVITIES

1.   Provide technical support and assistance for GMP production of a Tc-99m
Annexin V kit and components incorporating lyphilized Annexin V at a 1 mg
nominal fill using curent NeoRx radiotechnetium labeling technology. This will
use Tc-99m Veriuma technology for first generation Annexin V product. Duration 6
months.

2.   Attempt to develop techniques for Tc-99m labeling of Annexin V which do not
require final column separation step. Goals should be >85% yield with remainder
of radioactivity excreted by kidneys. Duration 18 months.

3.   Attempt to develop techniques for Tc-99m labeling techniques which are
effective with as little as 100 micrograms of Annexin V, providing much
increased specific activity of Tc-99m annexin V for injection. Yield, purity and
in vivo phosphatidyl serine targeting are to be maintained comparable to
readioiodine or Verluma kit standards. Duration 18 months.

5.   Provide technical support and advice to Theseus in the development of
Tc-99m Leukomate in the same kit format as Verluma using licensed NeoRx labeling
technology. Duration 3 months.

6.   Other research activities as mutually agreed upon that fit within the
quarterly research payment.

<PAGE>

           [*] CONFIDENTIAL TREATMENT REQUESTED. THE REDACTED MATERIAL
                 HAS BEEN FILED SEPARATELY WITH THE COMMISSION.

                       AMENDMENT ONE TO LICENSE AGREEMENT

     WHEREAS, this Amendment One amends that certain License Agreement dated
August 7, 1998, by and between NeoRx Corporation (hereinafter "NeoRx"), a
corporation organized under the laws of the State of Washington, having a place
of business at 410 West Harrison Street, Seattle, Washington 98119, and Theseus,
Ltd. (hereinafter "Theseus"), a corporation organized under the laws of the
State of Delaware, having a place of business at One Financial Center, Boston,
Massachusetts 02111, and

     WHEREAS, the parties are desirous of amending certain terms as are set out
below, said modifications to be effective August 7, 1999.

     NOW, THEREFORE, the August 7, 1998 License Agreement shall be amended as
follows:

Paragraph 2.05 shall be amended to extend the period of time in which NeoRx
provides assistance to Theseus regarding Boehringer Ingeheim technology, and
shall read as follows:

          "NeoRx shall provide reasonable assistance to Theseus, upon
          Theseus' request and at Theseus' expense, for a period of
          time up to and including August 7, 2000, in seeking other
          rights to technology owned or controlled by Boehringer
          Ingelheim that may be useful in connection with Annexin
          Licensed Products."

Paragraph 3.01(d) shall be amended to provide for cash payment only, and shall
read as follows:

     "[*] three (3) years after the Effective Date; and"

Paragraph 3.05(a)(i) shall be amended to modify the percentage rate, and shall
read as follows:

     "[*] of aggregate annual Net Sales of all such Annexin Licensed Products up
     to and including [*] and"

     All other terms and conditions of the License Agreement dated August 7,
1998 shall remain in full force and effect, as stated.

     Amendment One Effective August 7, 1999.

                                NeoRx Corporation

                                By:      /s/ Richard L. Anderson
                                    -------------------------------------------
                                         Richard L. Anderson
                                         President and Chief Operating Officer

                                Theseus, Ltd.

                                By:      /s/ Robert Bender
                                    -------------------------------------------

                                         Its      Vice President
                                             ----------------------------------<PAGE>

         [*] CONFIDENTIAL TREATMENT REQUESTED. THE REDACTED MATERIAL
                 HAS BEEN FILED SEPARATELY WITH THE COMMISSION.

                                  EXHIBIT 10.8

                                LICENSE AGREEMENT

Effective as of April 1, 1998 ("Effective Date"), THE BOARD OF TRUSTEES OF THE
LELAND STANFORD JUNIOR UNIVERSITY, a body having corporate powers under the laws
of the State of California ("STANFORD"), and THESEUS MEDICAL IMAGING, a Delaware
corporation having a principal place of business at One Financial Center,
Boston, MA 02111 ("LICENSEE"), agree as follows:

1.   BACKGROUND

1.1  STANFORD and University of Washington ("UW") has an assignment to "Imaging
     of Programmed Cell Death (Apoptosis) Using Technetium 99m Radiolabeled
     Annexin V" from the laboratories of Drs. H. William Strauss and Francis
     Blankenberg here at STANFORD and Dr. John Tait at UW ("Invention[s]"), as
     described in Stanford Docket S96-214, and any Licensed Patent(s), as
     hereinafter defined, which may issue to such Invention(s).

1.2  STANFORD has certain technical data and information as herein defined
     ("Technology") pertaining to Invention(s).

1.3  STANFORD desires to have the Technology and Invention(s) perfected and
     marketed at the earliest possible time in order Out products resulting
     therefrom may be available for public use and benefit.

1.4  LICENSEE desires a license under said Technology, Invention(s), and
     Licensed Patent(s) to develop, manufacture, use, and sell Licensed
     Product(s) in the field of use of Human and Veterinary Diagnosis.

1.5  The Technology and Invention(s) were made in the course of research
     supported by the National Institutes of Health and the Child Health
     Research Fund.

1.6  STANFORD has entered into an agreement with UW granting STANFORD authority
     to act on behalf of UW in connection with the licensing of UWs rights in
     the Inventions and Technology.

1.7  STANFORD asserts that it has the right to enter into this license agreement
     for the licensing of the rights to Invention(s) and Technology.

2.   DEFINITIONS

2.1  "Licensed Patent(s)" means any Letters Patent issued upon STANFORD's U.S.
     Provisional Patent Application, Serial Number 045399, filed April 30, 1997
     and/or any divisions, continuations, or reissues, reexaminations and
     extensions thereof as well as any continuation-in-part applications to the
     extent that the practice of the Invention as contemplated on the Effective
     Date would infringe the claims of any patent issuing from such
     continuation-in-part application.

2.2  "Technology" means existing technical data and information, including,
     but not limited to, the information contained in the Patent Application
     pertaining to the Invention(s) and provided to the LICENSEE whether or
     not it is of a confidential nature.

2.3  "Licensed Product(s)" means any product or part thereof in the Licensed
     Field of Use, the manufacture, use, or sale of which:

     (a) Is covered by a valid claim of an issued, unexpired Licensed
         Patent(s) directed to the Invention(s). A claim of an issued,
         unexpired Licensed Patent(s) shall be presumed to be valid unless
         and until it has been held to be invalid by a final judgment of a
         court of competent jurisdiction from which no appeal can be or is
         taken;

     (b) Is covered by any claim being prosecuted in a pending application
         directed to the Invention(s); or

     (c) Incorporates any of the Technology.

2.4 "Licensed Process(es)" means processes which, in the course of being
     practiced would, in the absence of this Agreement, infringe one or more
     claims of the Licensed Patents.

                                       -1-
<PAGE>

           [*] CONFIDENTIAL TREATMENT REQUESTED. THE REDACTED MATERIAL
                 HAS BEEN FILED SEPARATELY WITH THE COMMISSION.

2.5  "Net Sales" means the gross revenue derived by LICENSEE and/or
     sublicensee(s) from sales of Licensed Product(s) or practice of Licensed
     Processes, less the following item but only insofar as they actually
     pertain to the disposition of such Licensed Product(s) by LICENSEE or
     sublicensee(s), are included in such gross revenue, and are separately
     billed:

     (a)  Import, export, excise and sales taxes, and custom duties;

     (b)  Costs of insurance, packing, and transportation from the place of
          manufacture to the customer's premises or point of installation;

     (c)  Costs of installation at the place of use; and

     (d)  Credit for returns, allowances, or trades.

2.6  "Licensed Field of Use" means-Human and Veterinary Diagnostics.

2.7  "Licensed, Territory" means World-wide.

2.8  "Exclusive" means that, subject to Article 4 STANFORD shall not grant
     further licenses in the Licensed Territory in the Licensed Field of Use.

3.   GRANT

3.1  STANFORD hereby grants and LICENSEE hereby accepts a license in the
     Licensed Field of Use to make, use, and sell Licensed Product(s) in the
     Licensed Territory and to practice licensed Processes in the Licensed Field
     of Use.

3.2  Said license is Exclusive, including the right to sublicense pursuant to
     Article 13, in the Licensed Field of Use for a term commencing as of the
     Effective Date and ending upon the last to expire of Licensed Patent(s).

3.3  STANFORD shall have the right to practice: the Invention(s) and use the
     Technology for itself or in collaboration with third party academic or
     not-for-profit research institutions. STANFORD shall have the right to
     publish any information included in Technology and Licensed Patent(s).

4.   GOVERNMENT RIGHTS

This Agreement is subject to all of the terms and conditions of Title 35 United
States Code Sections 200 through 204, including an obligation that Licensed
Product(s) sold or produced in the United States be "manufactured substantially
in the United States," and LICENSEE agrees to take all reasonable action
necessary on its part as licensee to enable STANFORD to satisfy its obligation
thereunder, relating to Invention(s).

5.   DILIGENCE

5.1  As an inducement to STANFORD to enter into this Agreement, LICENSEE agrees
     to use all reasonable efforts and diligence to proceed with the
     development, manufacture, and sale or lease of Licensed Product(s) and
     Licensed Process(es) and to diligently develop markets for the Licensed
     Product(s) and Licensed Process(es). LICENSEE shall demonstrate diligence
     to STANFORD by achieving the goals outlined in Appendix A. In addition,
     LICENSEE agrees that STANFORD may terminate this Agreement if LICENSEE or a
     sublicensee(s) has not sold Licensed Product(s) or practiced Licensed
     Process(es) for a period of one (1) year.

5.2  PROGRESS REPORT - On or before September 1 of each year until LICENSEE
     markets a Licensed Product(s), LICENSEE shall make a written annual report
     to STANFORD covering the preceding year ending June 30, regarding the
     progress of LICENSEE toward commercial use of Licensed Product(s). Such
     report shall include, as a minimum, information sufficient to enable
     STANFORD to satisfy reporting requirements of the U.S. Government and for
     STANFORD to ascertain progress by LICENSEE toward meeting the diligence
     requirements of this Article 5.

6.   ROYALTIES

6.1  LICENSEE agrees to pay to STANFORD a noncreditable, nonrefundable license
     issue royalty of [*] upon signing this Agreement

6.2  Upon signing of this Agreement, LICENSEE will also issue to STANFORD
     preferred shares of LICENSEE stock equal to [*] of the total issued stock
     as of the Effective Date.

                                       2
<PAGE>

           [*] CONFIDENTIAL TREATMENT REQUESTED. THE REDACTED MATERIAL
                 HAS BEEN FILED SEPARATELY WITH THE COMMISSION.

6.3  LICENSEE also agrees to pay the following minimum annual royalties to
     STANFORD:

     ANNIVERSARY OF EFFECTIVE DATE           MINIMUM ANNUAL ROYALTY DUE
     -----------------------------           --------------------------
         First and Second                              [*]
         Third and Fourth                              [*]
         Fifth and Thereafter                          [*]

     These yearly royalty payments are nonrefundable, but are creditable
     against earned royalties to the extent provided in Paragraph 6-7. These
     yearly royalty payments are not considered delinquent if provided within 6
     months of the due date.

6.4  In addition, on the first and second anniversary of the Effective Date of
     this Agreement, LICENSEE will issue to STANFORD preferred shares of
     LICENSEE stock equal to 0.125% of the total shares issued on that date.

6.5  LICENSEE will also pay STANFORD earned royalties on Net Sales as follows:
     [*] on the first [*] of Net Sales annually [*] on additional Net Sales in
     excess of [*] Million annually.

     In the event that a royalty is paid to a third party for use of technology
     required to be licensed from such third party in order to practice STANFORD
     technology, if the royalty due the third party plus royalty payable to
     STANFORD for any Licensed Product exceeds two times the royalty due
     STANFORD, then the royalty due will be reduced by one-half of the excess
     above two times the royalty stated above.

6.6  LICENSEE also agrees to pay to STANFORD upon the occurrence of the
     following events, the following amounts:

EVENT                                                             MILESTONES
-----                                                             ----------
Upon the earlier of filing of a PLA in the United States-
or 5 1/2 years after the Effective Date                              [*]
Upon first Licensed Patent issuance                                  [*]
Upon filing of the first Marketing Application in the E.U.           [*]
Upon filing of a marketing application in Japan                      [*]
Upon issuance of marketing approval in the United States             [*]
Upon issuance of first marketing approval in the E.U.                [*]
Upon issuance of marketing approval in Japan                         [*]

6.7  Creditable payments under this Agreement shall be an offset to LICENSEE
     against up to [*] of each earned royalty payment which LICENSEE would be
     required to pay pursuant to Paragraph 6.5 until the entire credit is
     exhausted.

6.8  If this Agreement is not terminated in accordance with other provisions
     hereof, LICENSEE's obligation to pay royalties hereunder shall continue
     until the latter of:

     (a)  [*] years, if no Licensed Patent(s) issues; or

     (b)  For so long as LICENSEE, by its activities would, but for the license
          granted herein, infringe a valid claim of an unexpired Licensed
          Patent(s) of STANFORD covering said activity.

                                       3
<PAGE>

           [*] CONFIDENTIAL TREATMENT REQUESTED. THE REDACTED MATERIAL
                 HAS BEEN FILED SEPARATELY WITH THE COMMISSION.

6.9  The royalty on sales in currencies other than U.S. Dollars shall be
     calculated using the appropriate foreign exchange rate for such currency
     quoted by the Bank of America (San Francisco) foreign exchange desk on the
     close of business on the last banking day of each calendar quarter. Royalty
     payments to STANFORD shall be in U.S. Dollars. All non-U.S. taxes related
     to royalty payments shall be paid by LICENSEE and are not deductible from
     the payments due STANFORD.

6.10 Within thirty (30) days after receipt of a statement from STANFORD,
     LICENSEE shall reimburse STANFORD:

     (a)  [*] to offset patent expenses corresponding to the Invention(s)
          incurred by Stanford prior to the Effective Date; and

     (b)  for all costs incurred by Stanford in connection with the preparation,
          filing and prosecution of all patent applications and maintenance of
          patents corresponding to the Invention(s) after the Effective Date.

7.   ROYALTY REPORTS, PAYMENTS, AND ACCOUNTING

7.1  QUARTERLY EARNED ROYALTY PAYMENT AND REPORT - Beginning with the first sale
     of a Licensed Product(s), LICENSEE shall make written reports (even if
     there are no sales) and earned royalty payments to STANFORD within thirty
     (30) days after the end of each calendar quarter. This report will state
     the number, description, and aggregate Net Sales of Licensed Product(s)
     during such completed calendar quarter, and resulting calculation pursuant
     to Paragraph 6-5 of earned royalty payment due STANFORD for such completed
     calendar quarter. Concurrent with the making of each such report, LICENSEE
     shall include payment due STANFORD of royalties for the calendar quarter
     covered by such report.

7.2  ACCOUNTING - LICENSEE agrees to keep and maintain records for a period of
     three (3) years showing the manufacture, sale, use, and other disposition
     of products sold or otherwise disposed of under the license herein granted
     records will include general ledger records showing cash receipts and
     expenses, and records which included production on-records, customers,
     serial numbers, and related information in sufficient detail to enable the
     royalties payable hereunder by LICENSEE to be determined. LICENSEE further
     agrees to permit its books and records to be examined by STANFORD from time
     to time to the extent necessary to verify reports provided for in Paragraph
     7.1. Such examination is to be made by STANFORD or its designee, at the
     expense of STANFORD, except in the event that the results of the audit
     reveal an underreporting of royalties due STANFORD of [*] or more, then the
     audit costs shall be paid by LICENSEE.

8.   NEGATION OF WARRANTIES

8.1  Nothing in this Agreement is or shall be construed as:

     (a)  A warranty or representation by: STANFORD as to the validity or scope
          of any Licensed Patent(s);

     (b)  A warranty or representation that anything made, used, sold, or
          otherwise disposed of under any license granted in this Agreement is
          or will be free from infringement of patents, copyrights, and other
          rights of third parties;

     (c)  An obligation to bring or prosecute actions or suits against third
          parties for infringement, except to the extent and in the
          circumstances described in Article 12;

     (d)  Granting by implication, estoppel, or otherwise any licenses or rights
          under patents or other rights of STANFORD or other persons other than
          Licensed Patent(s), regardless of whether such patents or other rights
          are dominant or subordinate to any Licensed Patent(s); or

     (e)  An obligation to furnish any technology or technological information
          other than the Technology.

8.2  Except as expressly set forth in this Agreement, STANFORD MAKES NO
     REPRESENTATIONS AND EXTENDS NO WARRANTIES, OF ANY KIND, EITHER EXPRESS OR
     IMPLIED. THERE ARE NO EXPRESS OR IMPLIED WARRANTIES OF MERCHANTABILITY OR
     FITNESS FOR A PARTICULAR PURPOSE, OR THAT THE USE OF THE LICENSED
     PRODUCT(S) WILL NOT INFRINGE ANY PATENT, COPYRIGHT, TRADEMARK, OR OTHER
     RIGHTS OR ANY OTHER EXPRESS OR IMPLIED WARRANTIES.

                                       4
<PAGE>

           [*] CONFIDENTIAL TREATMENT REQUESTED. THE REDACTED MATERIAL
                 HAS BEEN FILED SEPARATELY WITH THE COMMISSION.

8.3  LICENSEE agrees that nothing in this Agreement grants LICENSEE any express
     or implied license or right under or to U.S. Patent 4,656,134
     "Amplification of Eucaryotic Genes" or any patent application corresponding
     thereto.

9.   INDEMNITY

9.1  LICENSEE agrees to indemnify, hold harmless, and defend STANFORD,
     UCSF-Stanford Health Care and Stanford Health Services and their respective
     trustees, officers, employees, students, and agents against any and all
     claims for death, illness, personal injury, property damage, and improper
     business practices arising out of the manufacture, use, sale, or other
     disposition of Invention(s), Licensed Patent(s), Licensed Product(s),
     Licensed Process(es) or Technology by LICENSEE or sublicensee(s), or their
     customers.

9.2  STANFORD shall not be liable for any indirect, special, consequential or
     other damages whatsoever, whether grounded in: tort (including negligence),
     strict liability, contract or otherwise. STANFORD shall not have any
     responsibilities or liabilities whatsoever with respect to Licensed
     Products(s).

9.3  LICENSEE shall at all times comply, through insurance or self-insurance,
     with all statutory workers' compensation and employers' liability
     requirements covering any and all employees with respect to activities
     performed under this Agreement.

9.4  In addition to the foregoing, LICENSEE shall maintain, during the term of
     this Agreement, Comprehensive General Liability Insurance, including
     Products Liability Insurance, with reputable and financially secure
     insurance carrier(s) to cover the activities of LICENSEE and its
     sublicensee(s). Such insurance shall provide minimum limits of liability of
     $5 Million and shall include STANFORD, UCSF-Stanford Health Care, Stanford
     Health Services, their trustees, directors, officers, employees, students,
     and agents as additional insureds. Such insurance shall be written to cover
     claims incurred, discovered, manifested, or made during or after the
     expiration of this Agreement and should be placed with carriers with
     ratings of at least A- as rated by A.M. Best Within 15 days of the
     Effective Date of this Agreement, LICENSEE shall furnish a Certificate of
     Insurance evidencing primary coverage and additional insured requirements
     and requiring thirty (30) days prior written notice of cancellation or
     material change to STANFORD. LICENSEE shall advise STANFORD, in writing,
     that it maintains excess liability coverage (following form) over primary
     insurance for at least the minimum limits set forth above. All such
     insurance of LICENSEE shall be primary coverage; insurance of STANFORD,
     UCSF-Stanford Health Care, and Stanford Health Services shall be excess and
     noncontributory.

10.  MARKING

Prior to the issuance of patents on the Invention(s), LICENSEE agrees to mark
Licensed Products (or their containers or labels) made, sold, or otherwise
disposed of by it under the license granted in this Agreement with the words
"Patent Pending," and following the issuance of one or more patents, with the
numbers of the Licensed Patent(s).

11.  STANFORD NAMES AND MARKS

LICENSEE agrees not to identify STANFORD in any promotional advertising or other
promotional materials to be disseminated to the public or any portion thereof or
to use the name of any STANFORD faculty member, employee, or student or any
trademark, service mark, trade name, or symbol of STANFORD, Stanford Health
Services or UCSF-Stanford Health Care, or that is associated with any of them,
without STANFORD's prior written consent.

12.  INFRINGEMENT BY OTHERS: PROTECTION OF PATENTS

12.1 LICENSEE shall promptly inform STANFORD of any suspect infringement of any
     Licensed Patent(s) by a third party. During the Exclusive period of this
     Agreement, STANFORD and LICENSEE each shall have the right to institute an
     action for infringement of the Licensed Patent(s) against such third party
     in accordance with the following:

     (a)  If STANFORD and LICENSEE agree to institute suit jointly, the suit
          shall be brought in both their names, the out-of-pocket costs thereof
          shall be borne equally, and any recovery or settlement shall be shared
          equally. LICENSEE and STANFORD shall agree to the manner in which they
          shall exercise control over such action. STANFORD may, if it so
          desires also be represented by separate counsel of its own selection,
          the, fees for which counsel shall be paid by STANFORD;

                                       5
<PAGE>

           [*] CONFIDENTIAL TREATMENT REQUESTED. THE REDACTED MATERIAL
                 HAS BEEN FILED SEPARATELY WITH THE COMMISSION.

     (b)  In the absence of agreement to institute a suit jointly, STANFORD may
          institute suit, and, at its option, join LICENSEE as a plaintiff. If
          STANFORD decides to institute suit, then it shall notify LICENSEE in
          writing. LICENSEE's failure to notify STANFORD in writing, within
          fifteen (15) days after the date of the notice, that it will join in
          enforcing the patent pursuant to the provisions hereof, shall be and
          be deemed conclusively to be LICENSEE's assignment to STANFORD of all
          rights, causes of action, and damages resulting from any such alleged
          infringement. STANFORD shall bear the entire cost of such litigation
          and shall be entitled to retain the entire amount of any recovery or
          settlement; and

     (c)  In the absence of agreement to institute a suit jointly and if
          STANFORD notifies LICENSEE that it has decided not to join in or
          institute a suit, as provided in (a) or (b) above, LICENSEE may
          institute suit and, at its option, join STANFORD as a plaintiff.
          LICENSEE shall bear the entire cost of such litigation. Any recovery
          in excess of litigation costs will be shared with STANFORD as follows:

          1.   Any payment for past sales will be deemed to be Net Sales and
               LICENSEE will pay STANFORD royalties thereon at the rates
               specified in Paragraph 6.6; and

          2.   any payment which covers future sales will be deemed a sublicense
               and royalties will be shared as specified in Article 13.

          LICENSEE and STANFORD agree to negotiate in good faith an appropriate
          compensation to STANFORD for any non-cash settlement or non-cash
          cross-license. STANFORD will not share in the portion of the recovery,
          if any, that is payment for "willful infringement."

12.2 Should either STANFORD or LICENSEE commence a suit under the provisions o
     Paragraph 12.1 and thereafter elect to abandon the-same, it shall give
     timely notice to the other party who may, if it so desires, continue
     prosecution of such suit, provided, however, that the sharing of expenses
     and any recovery in such suit shall be as agreed upon between STANFORD and
     LICENSEE.

13.  SUBLICENSE(S)

13.1 LICENSEE may grant sublicense(s) during the Exclusive period.

13.2 If LICENSEE is unable or unwilling to serve or develop a potential market
     or market territory for which there is a willing sublicensee(s), LICENSEE
     will, at STANFORD's request, negotiate in good faith a sublicense(s)
     hereunder.

13.3 Any sublicense(s) granted by LICENSEE under this Agreement shall be subject
     and subordinate to terms and conditions of this Agreement, except:

     (a)  Sublicense terms and conditions shall reflect that any
          sublicensee(s) shall not further sublicense; and

     (b)  The earned royalty rate specified in the sublicense(s) may be at
          higher rates than the rates in this Agreement.

     Any such sublicense(s) also shall expressly include the provisions of
     Articles 7, 8, and 9 for the benefit of STANFORD and provide for the
     transfer of all obligations, including the payment of royalties specified
     in such sublicense(s), to STANFORD or its designee, in the event that this
     Agreement is terminated.

13.4 LICENSEE agrees to provide STANFORD a copy of any sublicense granted
     pursuant to this Article 13.

13.5 LICENSEE will pay to STANFORD [*] of all payments received through
     sublicensing in addition to earned royalty income received by LICENSEE from
     its sublicensee(s) which is payable to STANFORD pursuant to Article 6.

14.  TERMINATION

14.1 LICENSEE may terminate this Agreement by giving STANFORD notice in writing
     at least thirty (30) days in advance of the effective date of termination
     selected by LICENSEE.

14.2 STANFORD may terminate this Agreement if: LICENSEE:

     (a)  Is in default in payment of royalty or providing of reports;

     (b)  Is in breach of any provision hereof; or

     (c)  Provides any false report; and LICENSEE fails to remedy any such
          default, breach, or false report within thirty (30) days after written
          notice thereof by STANFORD.

                                       6
<PAGE>

           [*] CONFIDENTIAL TREATMENT REQUESTED. THE REDACTED MATERIAL
                 HAS BEEN FILED SEPARATELY WITH THE COMMISSION.

14.3 Surviving any termination are:

     (a)  LICENSEE's obligation to pay royalties accrued or accruable;

     (b)  Any cause of action or claim of LICENSEE or STANFORD, accrued or to
          accrue, because of any breach or default by the other party; and

     (c)  The provisions of Articles 7, 8, and 9.

15.  ASSIGNMENT

This Agreement may not be assigned.

16.  ARBITRATION

16.1 Any controversy arising under or related to this Agreement, and any
     disputed claim by either party against the other under this Agreement
     excluding any dispute relating to patent validity or infringement arising
     under this Agreement, shall be settled by arbitration in accordance with
     the Licensing Agreement Arbitration Rules of the American Arbitration
     Association.

16.2 Upon request by either party, arbitration will be by a third party
     arbitrator mutually agreed upon in writing by LICENSEE and STANFORD within
     thirty (30) days of such arbitration request. Judgment upon the award
     rendered by the arbitrator shall be final and nonappealable and may be
     entered in any court having jurisdiction thereof.

16.3 The parties shall be entitled to discovery in like manner as if the
     arbitration were a civil suit in the California Superior Court. The
     Arbitrator may limit the scope, time and/or issues involved in discovery.

16.4 Any arbitration shall be held at Stanford, California, unless the parties
     hereto mutually agree in writing to another place.

17.  NOTICES

All notices under this Agreement shall be deemed to have been fully given when
done in writing and deposited in the United States mail, registered or
certified, and addressed as follows:

             To STANFORD:        Office of Technology Licensing
                                 Stanford University
                                 900 Welch Road, Suite 350
                                 Palo Alto, CA 94304-18M
                                 Attention: Director

             To LICENSEE:        Theseus Medical Imaging
                                 One Financial Center
                                 Boston, MA 02111
                                 Attention:

   Either party may change its address upon written notice to the other party.

18.  WAIVER

None of the terms of this Agreement can be waived except by the written consent
of the party waiving compliance.

19.  APPLICABLE LAW

This Agreement shall be governed by the laws of the State of California
applicable to agreements negotiated, executed and performed wholly within
California.

                                       7
<PAGE>

           [*] CONFIDENTIAL TREATMENT REQUESTED. THE REDACTED MATERIAL
                 HAS BEEN FILED SEPARATELY WITH THE COMMISSION.

IN WITNESS WHEREOF, the parties hereto have executed this Agreement in duplicate
originals by their duly authorized officers or representatives.

                  THE BOARD OF TRUSTEES OF THE LELAND
                  STANFORD JUNIOR UNIVERSITY

                  Signature         /s/ KATHERINE KU
                           -----------------------------------------------------
                  Name              KATHERINE KU
                       ---------------------------------------------------------
                  Title             DIRECTOR, TECHNOLOGY LICENSING
                       ---------------------------------------------------------

                  THESEUS MEDICAL IMAGING

                  Signature         /s/ ROBERT BENDER
                           -----------------------------------------------------
                  Name              ROBERT BENDER
                       ---------------------------------------------------------
                  Title             VICE PRESIDENT AND DIRECTOR
                       ---------------------------------------------------------

                                       8
<PAGE>

           [*] CONFIDENTIAL TREATMENT REQUESTED. THE REDACTED MATERIAL
                 HAS BEEN FILED SEPARATELY WITH THE COMMISSION.

                                   Appendix A

Goals - Time from Effective Date of the Agreement

Within 15 months:
     GMP Production of Annexin V as the basis of a radiopharmaceutical product
suitable for human use.

Within 18 months:
     Filing of IND to initiate human clinical trials of imaging product
incorporating license technology.

Within 30 months:
     Initiation of Phase III clinical trials of diagnostic product incorporating
licensed technology.

Within 48 months:
         Filing of PLA (license application) with FDA in US.

Within 48 months:
         Filing of marketing application in the European Union.

<PAGE>

           [*] CONFIDENTIAL TREATMENT REQUESTED. THE REDACTED MATERIAL
                 HAS BEEN FILED SEPARATELY WITH THE COMMISSION.

                                 AMENDMENT NO. 1

                                     to the

                                License Agreement

                             Effective April 1, 1998

                                     Between

                               STANFORD UNIVERSITY

                                       and

                             THESEUS MEDICAL IMAGING

1.   BACKGROUND

1.1  STANFORD and THESEUS are parties to a License Agreement effective April 1,
     1998 ("Original Agreement") covering "Imaging of Programmed Cell Death
     (Apoptosis) Using Technetium 99m Radiolabled Annexin V" hereinafter
     referred to as "Invention" as described in Stanford Docket S96-214.

1.2  To facilitate the sale of THESEUS and the commercialization of the
     Invention, THESEUS desires a reduction in earned royalties owed to
     STANFORD.

1.3  To commercialize the Invention, THESEUS has licensed patents from two other
     parties. Both of these parties have verbally agreed to a similar reduction
     in royalties.

1.4  THESEUS has issued common shares of stock and has not issued preferred
     shares.

2.   AMENDMENTS

2.1  Delete Paragraph 2.5 of Original Agreement and replace with the following:
     "2.4 Net Sales" means the gross amounts invoiced for sales of Licensed
     Products or practice of Licensed Processes by LICENSEE, its Affiliates or
     sublicensees, less (a) discounts actually granted, (b) credits or
     allowances granted upon claims, damaged goods, rejections or returns of
     Licensed Products, including recalls, (c) freight, postage shipping and
     insurance charges actually allowed or paid for delivery of Licensed
     Products, to the extent billed, and (d) taxes, duties or other governmental
     charges (0ther than income taxes and non-U.S. taxes to be paid by LICENSEE
     under paragraph 6.9) levied on, absorbed or otherwise imposed on sales of
     Licensed Products."

2.2  Add Paragraph 2.9 to Original Agreement as follows: "2.9 "Affiliates" means
     any person, corporation, or other business entity which controls, is
     controlled by, or is under common control with LICENSEE; and for this
     purpose, "control" of a corporation means the direct or indirect ownership
     of more than fifty percent (50%) of its voting stock, and "control" of any
     other business entity means the direct or indirect ownership of greater
     than fifty percent (50%) interest in the income of such entity.

2.3  Delete paragraph 6.2 of Original Agreement and replace with the following:
     "6.2 LICENSEE will also issue to STANFORD common shares of LICENSEE stock
     equal to 0.25% of the total stock as of the Effective Date."

<PAGE>

           [*] CONFIDENTIAL TREATMENT REQUESTED. THE REDACTED MATERIAL
                 HAS BEEN FILED SEPARATELY WITH THE COMMISSION.

2.4  Delete Paragraph 6.5 and replace with the following: "6.5 LICENSEE will
     also pay STANFORD [*] earned royalties on Net Sales. In the event that a
     royalty is paid to a third party for use of technology required to be
     licensed from such third party in order to practice STANFORD technology, if
     the royalty due the third party plus the royalty payable to STANFORD for
     any Licensed Product exceeds two times the royalty due STANFORD, then the
     royalty due will be reduced by one-half of the excess above two times the
     royalty stated above."

3.   This Amendment will be effective when THESEUS has met its obligations under
     the Original Agreement, in particular, Paragraph 6.2 of the Original
     Agreement.

4.   All other terms and conditions of the Original Agreement will remain in
     full force and effect.

IN WITNESS WHEREOF, the parties hereto have executed these presents in duplicate
by their duly authorized officers or representatives.

                  THE BOARD OF TRUSTEES OF THE LELAND
                  STANFORD JUNIOR UNIVERSITY

                  Signature         /s/ KATHERINE KU
                           -----------------------------------------------------
                  Name
                      ----------------------------------------------------------
                  Title
                       ---------------------------------------------------------
                  Date
                      ----------------------------------------------------------

                  THESEUS MEDICAL IMAGING

                  Signature         /s/ ROBERT BENDER
                           -----------------------------------------------------
                  Name
                      ----------------------------------------------------------
                  Title
                       ---------------------------------------------------------
                  Date
                      ----------------------------------------------------------

                                       2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00019-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00019-of-00352.parquet"}]]